Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies

WHO. A blueprint for dementia research. Geneva: World Health Organization (2022).

Knopman, D. S. et al. Alzheimer disease. Nat. Rev. Dis. Prim. 7, 33 (2021).

Article
PubMed

Google Scholar

Querfurth, H. W. & LaFerla, F. M. Alzheimer’s disease. N. Engl. J. Med. 362, 329–344 (2010).

Article
CAS
PubMed

Google Scholar

2023 Alzheimer’s disease facts and figures. Alzheimers Dement. 19, 1598–1695 (2023).

Abdelnour, C. et al. Perspectives and challenges in patient stratification in Alzheimer’s disease. Alzheimers Res. Ther. 14, 112 (2022).

Article
PubMed
PubMed Central

Google Scholar

Cummings, J. New approaches to symptomatic treatments for Alzheimer’s disease. Mol. Neurodegener. 16, 2 (2021).

Article
PubMed
PubMed Central

Google Scholar

Graff-Radford, J. et al. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol. 20, 222–234 (2021).

Article
PubMed
PubMed Central

Google Scholar

Falgàs, N., Walsh, C. M., Neylan, T. C. & Grinberg, L. T. Deepen into sleep and wake patterns across Alzheimer’s disease phenotypes. Alzheimers Dement. 17, 1403–1406 (2021).

Article
PubMed

Google Scholar

Atri, A. The Alzheimer’s disease clinical spectrum: diagnosis and management. Med. Clin. North Am. 103, 263–293 (2019).

Article
PubMed

Google Scholar

Maciejewska, K., Czarnecka, K. & Szymański, P. A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease. Pharm. Rep. 73, 1565–1581 (2021).

Article

Google Scholar

Dubois, B. et al. Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimers Res. Ther. 15, 175 (2023).

Article
PubMed
PubMed Central

Google Scholar

Katabathula, S., Davis, P. B. & Xu, R. Comorbidity-driven multi-modal subtype analysis in mild cognitive impairment of Alzheimer’s disease. Alzheimers Dement. 19, 1428–1439 (2023).

Article
PubMed

Google Scholar

Gong, X. et al. A red-emitting mitochondria targetable fluorescent probe for detecting viscosity in HeLa, zebrafish, and mice. Anal. Methods 16, 293–300 (2024).

Article
CAS
PubMed

Google Scholar

Wang, S. et al. ALDH2 contributes to melatonin-induced protection against APP/PS1 mutation-prompted cardiac anomalies through cGAS-STING-TBK1-mediated regulation of mitophagy. Signal Transduct. Target Ther. 5, 119 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Salasova, A., Monti, G., Andersen, O. M. & Nykjaer, A. Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease. Mol. Neurodegener. 17, 74 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Marde, V. S. et al. Alzheimer’s disease and sleep disorders: Insights into the possible disease connections and the potential therapeutic targets. Asian J. Psychiatr. 68, 102961 (2022).

Article
PubMed

Google Scholar

Fehsel, K. & Christl, J. Comorbidity of osteoporosis and Alzheimer’s disease: Is ‘AKT ‘-ing on cellular glucose uptake the missing link? Ageing Res. Rev. 76, 101592 (2022).

Article
CAS
PubMed

Google Scholar

Gunes, S. et al. Biomarkers for Alzheimer’s disease in the current state: a narrative review. Int J. Mol. Sci. 23, 4962 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Song, T. et al. Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer’s disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies. Ageing Res. Rev. 72, 101503 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Lloret, A. et al. When does Alzheimer’s disease really start? The role of biomarkers. Int J. Mol. Sci. 20, 5536 (2019).

Article
CAS
PubMed
PubMed Central

Google Scholar

Porsteinsson, A. P. et al. Diagnosis of early Alzheimer’s disease: Clinical practice in 2021. J. Prev. Alzheimers Dis. 8, 371–386 (2021).

CAS
PubMed

Google Scholar

Nedelec, T. et al. Identifying health conditions associated with Alzheimer’s disease up to 15 years before diagnosis: an agnostic study of French and British health records. Lancet Digit. Health 4, e169–e178 (2022).

Article
CAS
PubMed

Google Scholar

Zhang, X. X. et al. The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention. J. Prev. Alzheimers Dis. 8, 313–321 (2021).

PubMed

Google Scholar

Logroscino, G. Prevention of Alzheimer’s disease and dementia: the evidence is out there, but new high-quality studies and implementation are needed. J. Neurol. Neurosurg. Psychiatry 91, 1140–1141 (2020).

Article
PubMed

Google Scholar

Crous-Bou, M., Minguillón, C., Gramunt, N. & Molinuevo, J. L. Alzheimer’s disease prevention: from risk factors to early intervention. Alzheimers Res. Ther. 9, 71 (2017).

Article
PubMed
PubMed Central

Google Scholar

Omura, J. D. et al. Modifiable Risk Factors for Alzheimer Disease and Related Dementias Among Adults Aged ≥45 Years – United States, 2019. MMWR Morb. Mortal. Wkly Rep. 71, 680–685 (2022).

Article
PubMed
PubMed Central

Google Scholar

Zhang, D. F. & Li, M. Toward a Full Understanding of Causal and Modifiable Risk Factors for Alzheimer’s Disease by Integrative Phenome-wide Association Studies. Biol. Psychiatry 93, 756–758 (2023).

Article
PubMed

Google Scholar

Silva, M. V. F. et al. Alzheimer’s disease: risk factors and potentially protective measures. J. Biomed. Sci. 26, 33 (2019).

Article
PubMed
PubMed Central

Google Scholar

Beata, B. K. et al. Alzheimer’s Disease-Biochemical and Psychological Background for Diagnosis and Treatment. Int J. Mol. Sci. 24, 1059 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Thakral, S. et al. Alzheimer’s disease: Molecular aspects and treatment opportunities using herbal drugs. Ageing Res. Rev. 88, 101960 (2023).

Article
CAS
PubMed

Google Scholar

Stanciu, G. D. et al. Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement. Biomolecules 10, 40 (2019).

Article
PubMed
PubMed Central

Google Scholar

Hampel, H., Lista, S. & Khachaturian, Z. S. Development of biomarkers to chart all Alzheimer’s disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement. 8, 312–336 (2012).

Article
CAS
PubMed

Google Scholar

Sutphen, C. L., Fagan, A. M. & Holtzman, D. M. Progress update: fluid and imaging biomarkers in Alzheimer’s disease. Biol. Psychiatry 75, 520–526 (2014).

Article
PubMed

Google Scholar

Lista, S. et al. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer’s disease. Alzheimers Dement. 10, 381–392 (2014).

Article
PubMed

Google Scholar

Reiman, E. M. Alzheimer disease in 2016: Putting AD treatments and biomarkers to the test. Nat. Rev. Neurol. 13, 74–76 (2017).

Article
PubMed

Google Scholar

Davis, K. L. & Powchik, P. Tacrine. Lancet 345, 625–630 (1995).

Article
CAS
PubMed

Google Scholar

Qizilbash, N. et al. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists’ Collaboration. JAMA 280, 1777–1782 (1998).

Article
CAS
PubMed

Google Scholar

Jarrott, B. Tacrine: In vivo veritas. Pharm. Res. 116, 29–31 (2017).

Article

Google Scholar

Watkins, P. B. et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 271, 992–998 (1994).

Article
CAS
PubMed

Google Scholar

de Los Ríos, C. & Marco-Contelles, J. Tacrines for Alzheimer’s disease therapy. III. The PyridoTacrines. Eur. J. Med. Chem. 166, 381–389 (2019).

Article

Google Scholar

Birks, J. S. & Harvey, R. J. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst. Rev. 6, CD001190 (2018).

PubMed

Google Scholar

Cui, X. et al. Donepezil, a drug for Alzheimer’s disease, promotes oligodendrocyte generation and remyelination. Acta Pharm. Sin. 40, 1386–1393 (2019).

Article
CAS

Google Scholar

Brewster, J. T. 2nd, Dell’Acqua, S., Thach, D. Q. & Sessler, J. L. Classics in Chemical Neuroscience: Donepezil. ACS Chem. Neurosci. 10, 155–167 (2019).

Article
CAS
PubMed

Google Scholar

Feldman, H. H. & Lane, R. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 78, 1056–1063 (2007).

Article
PubMed
PubMed Central

Google Scholar

Rösler, M. et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 318, 633–638 (1999).

Article
PubMed
PubMed Central

Google Scholar

Coyle, J. & Kershaw, P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s disease. Biol. Psychiatry 49, 289–299 (2001).

Article
CAS
PubMed

Google Scholar

Scott, L. J. & Goa, K. L. Galantamine: a review of its use in Alzheimer’s disease. Drugs 60, 1095–1122 (2000).

Article
CAS
PubMed

Google Scholar

Marco-Contelles, J. et al. Synthesis and pharmacology of galantamine. Chem. Rev. 106, 116–133 (2006).

Article
CAS
PubMed

Google Scholar

Robinson, D. M. & Keating, G. M. Memantine: a review of its use in Alzheimer’s disease. Drugs 66, 1515–1534 (2006).

Article
CAS
PubMed

Google Scholar

Reisberg, B. et al. Memantine in moderate-to-severe Alzheimer’s disease. N. Engl. J. Med. 348, 1333–1341 (2003).

Article
CAS
PubMed

Google Scholar

Greig, S. L. Memantine ER/Donepezil: A Review in Alzheimer’s Disease. CNS Drugs 29, 963–970 (2015).

Article
CAS
PubMed

Google Scholar

Deardorff, W. J. & Grossberg, G. T. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease. Drug Des. Dev. Ther. 10, 3267–3279 (2016).

Article
CAS

Google Scholar

Benek, O., Korabecny, J. & Soukup, O. A Perspective on Multi-target Drugs for Alzheimer’s Disease. Trends Pharm. Sci. 41, 434–445 (2020).

Article
CAS
PubMed

Google Scholar

Syed, Y. Y. Sodium Oligomannate: First Approval. Drugs 80, 441–444 (2020).

Article
PubMed

Google Scholar

Wang, T. et al. A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia. Alzheimers Res. Ther. 12, 110 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Xiao, S. et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia. Alzheimers Res. Ther. 13, 62 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Cummings, J. & Salloway, S. Aducanumab: Appropriate use recommendations. Alzheimers Dement 18, 531–533 (2022).

Article
CAS
PubMed

Google Scholar

Dhillon, S. Aducanumab: First Approval. Drugs 81, 1437–1443 (2021).

Article
CAS
PubMed

Google Scholar

Behl, T. et al. “Aducanumab” making a comeback in Alzheimer’s disease: An old wine in a new bottle. Biomed. Pharmacother. 148, 112746 (2022).

Larkin, H. D. Lecanemab Gains FDA Approval for Early Alzheimer Disease. JAMA 329, 363 (2023).

Article
PubMed

Google Scholar

Harris, E. Alzheimer Drug Lecanemab Gains Traditional FDA Approval. JAMA 330, 495 (2023).

PubMed

Google Scholar

van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 388, 9–21 (2023).

Article
PubMed

Google Scholar

Sims, J. R. et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 330, 512–527 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Hippius, H. & Neundörfer, G. The discovery of Alzheimer’s disease. Dialogues Clin. Neurosci. 5, 101–108 (2003).

Article
PubMed
PubMed Central

Google Scholar

Hajjo, R., Sabbah, D. A., Abusara, O. H. & Al Bawab, A. Q. A Review of the Recent Advances in Alzheimer’s Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics. Diagnostics 12, 2975 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Burns, S. et al. Therapeutics of Alzheimer’s Disease: Recent Developments. Antioxidants 11, 2402 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Chen, J. et al. Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development. J. Med. Chem. 65, 5184–5211 (2022).

Article
CAS
PubMed

Google Scholar

Feng, L. et al. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives. Med. Res. Rev. 42, 710–743 (2022).

Article
CAS
PubMed

Google Scholar

Tan, L. et al. Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy. J. Med. Chem. 65, 5149–5183 (2022).

Article
CAS
PubMed

Google Scholar

Silva, G. M. et al. Allosteric Modulators of Potential Targets Related to Alzheimer’s Disease: a Review. ChemMedChem 14, 1467–1483 (2019).

Article
CAS
PubMed

Google Scholar

Wu, P., Clausen, M. H. & Nielsen, T. E. Allosteric small-molecule kinase inhibitors. Pharm. Ther. 156, 59–68 (2015).

Article
CAS

Google Scholar

Boike, L., Henning, N. J. & Nomura, D. K. Advances in covalent drug discovery. Nat. Rev. Drug Discov. 21, 881–898 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

He, M. et al. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduct. Target Ther. 7, 181 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Scott, D. E., Bayly, A. R., Abell, C. & Skidmore, J. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat. Rev. Drug Discov. 15, 533–550 (2016).

Article
CAS
PubMed

Google Scholar

Blazer, L. L. & Neubig, R. R. Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. Neuropsychopharmacology 34, 126–141 (2009).

Article
CAS
PubMed

Google Scholar

Liu, P. P., Xie, Y., Meng, X. Y. & Kang, J. S. History and progress of hypotheses and clinical trials for Alzheimer’s disease. Signal Transduct. Target Ther. 4, 29 (2019).

Article
PubMed
PubMed Central

Google Scholar

Fedele, E. Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis. Int. J. Mol. Sci. 24, 14499 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Kepp, K. P. et al. The amyloid cascade hypothesis: an updated critical review. Brain 146, 3969–3990 (2023).

Article
PubMed

Google Scholar

Rubin, L. et al. Genetic Risk Factors for Alzheimer’s Disease in Racial/Ethnic Minority Populations in the U.S.: A Scoping Review. Front. Public Health 9, 784958 (2021).

Article
PubMed
PubMed Central

Google Scholar

Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat. Genet. 51, 414–430 (2019).

Article
CAS
PubMed
PubMed Central

Google Scholar

Andrews, S. J. et al. The complex genetic architecture of Alzheimer’s disease: novel insights and future directions. EBioMedicine 90, 104511 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat. Genet. 54, 412–436 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Hampel, H. et al. The Amyloid-β Pathway in Alzheimer’s Disease. Mol. Psychiatry 26, 5481–5503 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Eid, A., Mhatre, I. & Richardson, J. R. Gene-environment interactions in Alzheimer’s disease: A potential path to precision medicine. Pharm. Ther. 199, 173–187 (2019).

Article
CAS

Google Scholar

Boyd, R. J., Avramopoulos, D., Jantzie, L. L. & McCallion, A. S. Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases. J. Neuroinflamm. 19, 223 (2022).

Article

Google Scholar

Rahman, M. A. et al. Emerging risk of environmental factors: insight mechanisms of Alzheimer’s diseases. Environ. Sci. Pollut. Res. Int. 27, 44659–44672 (2020).

Article
PubMed

Google Scholar

Galton, C. J., Patterson, K., Xuereb, J. H. & Hodges, J. R. Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 123, 484–498 (2000).

Article
PubMed

Google Scholar

Sirkis, D. W. et al. Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease. Mol. Psychiatry 27, 2674–2688 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Lam, B. et al. Clinical, imaging, and pathological heterogeneity of the Alzheimer’s disease syndrome. Alzheimers Res. Ther. 5, 1 (2013).

Article
PubMed
PubMed Central

Google Scholar

Aisen, P. S. et al. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res. Ther. 9, 60 (2017).

Article
PubMed
PubMed Central

Google Scholar

Morató, X. et al. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. Int. J. Mol. Sci. 23, 9305 (2022).

Article
PubMed
PubMed Central

Google Scholar

Selkoe, D. J. Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev. 81, 741–766 (2001).

Article
CAS
PubMed

Google Scholar

Whitehouse, P. J. et al. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237–1239 (1982).

Article
CAS
PubMed

Google Scholar

Perry, E. Acetylcholine and Alzheimer’s disease. Br. J. Psychiatry 152, 737–740 (1988).

Article
CAS
PubMed

Google Scholar

Tagliavini, F. & Pilleri, G. Neuronal counts in basal nucleus of Meynert in Alzheimer disease and in simple senile dementia. Lancet 1, 469–470 (1983).

Article
CAS
PubMed

Google Scholar

Li, J., Sun, M., Cui, X. & Li, C. Protective Effects of Flavonoids against Alzheimer’s Disease: Pathological Hypothesis, Potential Targets, and Structure-Activity Relationship. Int J. Mol. Sci. 23, 10020 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Auld, D. S., Kornecook, T. J., Bastianetto, S. & Quirion, R. Alzheimer’s disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol. 68, 209–245 (2002).

Article
CAS
PubMed

Google Scholar

Chen, Z. R., Huang, J. B., Yang, S. L. & Hong, F. F. Role of Cholinergic Signaling in Alzheimer’s Disease. Molecules 27, 1816 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Chen, X. Q. & Mobley, W. C. Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses. Front. Neurosci. 13, 446 (2019).

Article
PubMed
PubMed Central

Google Scholar

Hampel, H. et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 141, 1917–1933 (2018).

Article
PubMed
PubMed Central

Google Scholar

Giacobini, E., Cuello, A. C. & Fisher, A. Reimagining cholinergic therapy for Alzheimer’s disease. Brain 145, 2250–2275 (2022).

Article
PubMed

Google Scholar

Breijyeh, Z. & Karaman, R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules 25, 5789 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Ferreira-Vieira, T. H., Guimaraes, I. M., Silva, F. R. & Ribeiro, F. M. Alzheimer’s disease: Targeting the Cholinergic System. Curr. Neuropharmacol. 14, 101–115 (2016).

Article
CAS
PubMed
PubMed Central

Google Scholar

Bekdash, R. A. The Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimer’s Disease. Int. J. Mol. Sci. 22, 1273 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Berry, A. S. & Harrison, T. M. New perspectives on the basal forebrain cholinergic system in Alzheimer’s disease. Neurosci. Biobehav. Rev. 150, 105192 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Majdi, A. et al. Amyloid-β, tau, and the cholinergic system in Alzheimer’s disease: seeking direction in a tangle of clues. Rev. Neurosci. 31, 391–413 (2020).

Article
CAS
PubMed

Google Scholar

Malik, R. et al. Overview of therapeutic targets in management of dementia. Biomed. Pharmacother. 152, 113168 (2022).

Article
CAS
PubMed

Google Scholar

Moreira, F. T. C., Sale, M. G. F. & Di Lorenzo, M. Towards timely Alzheimer diagnosis: A self-powered amperometric biosensor for the neurotransmitter acetylcholine. Biosens. Bioelectron. 87, 607–614 (2017).

Article
CAS
PubMed

Google Scholar

Schneider, L. S. et al. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J. Intern. Med. 275, 251–283 (2014).

Article
CAS
PubMed
PubMed Central

Google Scholar

Morris, J. C. et al. Autosomal dominant and sporadic late onset Alzheimer’s disease share a common in vivo pathophysiology. Brain 145, 3594–3607 (2022).

Article
PubMed
PubMed Central

Google Scholar

O’Brien, R. J. & Wong, P. C. Amyloid precursor protein processing and Alzheimer’s disease. Annu. Rev. Neurosci. 34, 185–204 (2011).

Article
PubMed
PubMed Central

Google Scholar

Chen, G. F. et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharm. Sin. 38, 1205–1235 (2017).

Article
CAS

Google Scholar

Lanoiselée, H. M. et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med. 14, e1002270 (2017).

Article
PubMed
PubMed Central

Google Scholar

Pimplikar, S. W. et al. Amyloid-independent mechanisms in Alzheimer’s disease pathogenesis. J. Neurosci. 30, 14946–14954 (2010).

Article
CAS
PubMed
PubMed Central

Google Scholar

Lee, J. H. et al. Faulty autolysosome acidification in Alzheimer’s disease mouse models induces autophagic build-up of Abeta in neurons, yielding senile plaques. Nat. Neurosci. 25, 688–701 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Sun, L., Zhou, R., Yang, G. & Shi, Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase. Proc. Natl Acad. Sci. USA 114, E476–E485 (2017).

Article
CAS
PubMed

Google Scholar

Ullah, R., Park, T. J., Huang, X. & Kim, M. O. Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer’s pathology: Insights and therapeutic approaches from periphery. Ageing Res. Rev. 71, 101451 (2021).

Article
CAS
PubMed

Google Scholar

Ayton, S. & Bush, A. I. beta-amyloid: The known unknowns. Ageing Res. Rev. 65, 101212 (2021).

Article
CAS
PubMed

Google Scholar

Raulin, A. C. et al. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies. Mol. Neurodegener. 17, 72 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Verghese, P. B., Castellano, J. M. & Holtzman, D. M. Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol. 10, 241–252 (2011).

Article
CAS
PubMed
PubMed Central

Google Scholar

Koutsodendris, N., Nelson, M. R., Rao, A. & Huang, Y. Apolipoprotein E and Alzheimer’s Disease: Findings, Hypotheses, and Potential Mechanisms. Annu. Rev. Pathol. 17, 73–99 (2022).

Article
CAS
PubMed

Google Scholar

Bu, G. Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333–344 (2009).

Article
CAS
PubMed
PubMed Central

Google Scholar

Serrano-Pozo, A., Das, S. & Hyman, B. T. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 20, 68–80 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Troutwine, B. R. et al. Apolipoprotein E and Alzheimer’s disease. Acta Pharm. Sin. B 12, 496–510 (2022).

Article
CAS
PubMed

Google Scholar

Rosenberg, R. N., Lambracht-Washington, D., Yu, G. & Xia, W. Genomics of Alzheimer Disease: A Review. JAMA Neurol. 73, 867–874 (2016).

Article
PubMed
PubMed Central

Google Scholar

Nicolas, G. Recent advances in Alzheimer disease genetics. Curr. Opin. Neurol. 37, 154–165 (2024).

Article
CAS
PubMed

Google Scholar

Cline, E. N., Bicca, M. A., Viola, K. L. & Klein, W. L. The Amyloid-beta Oligomer Hypothesis: Beginning of the Third Decade. J. Alzheimers Dis. 64, S567–S610 (2018).

Article
CAS
PubMed
PubMed Central

Google Scholar

Giuffrida, M. L. et al. The monomer state of beta-amyloid: where the Alzheimer’s disease protein meets physiology. Rev. Neurosci. 21, 83–93 (2010).

Article
CAS
PubMed

Google Scholar

Kent, S. A., Spires-Jones, T. L. & Durrant, C. S. The physiological roles of tau and Abeta: implications for Alzheimer’s disease pathology and therapeutics. Acta Neuropathol. 140, 417–447 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Zhang, Y. et al. Amyloid beta-based therapy for Alzheimer’s disease: challenges, successes and future. Signal Transduct. Target Ther. 8, 248 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Cline, E. N., Bicca, M. A., Viola, K. L. & Klein, W. L. The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. J. Alzheimers Dis. 64, S567–S610 (2018).

Article
CAS
PubMed
PubMed Central

Google Scholar

Yu, H. & Wu, J. Amyloid-beta: A double agent in Alzheimer’s disease? Biomed. Pharmacother. 139, 111575 (2021).

Article
CAS
PubMed

Google Scholar

Lee, S. J. et al. Towards an understanding of amyloid-beta oligomers: characterization, toxicity mechanisms, and inhibitors. Chem. Soc. Rev. 46, 310–323 (2017).

Article
CAS
PubMed

Google Scholar

Viles, J. H. Imaging Amyloid-β Membrane Interactions: Ion-Channel Pores and Lipid-Bilayer Permeability in Alzheimer’s Disease. Angew. Chem. Int. Ed. Engl. 62, e202215785 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Salminen, A. et al. Inflammation in Alzheimer’s disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog. Neurobiol. 87, 181–194 (2009).

Article
CAS
PubMed

Google Scholar

White, J. A. et al. Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol. Dis. 18, 459–465 (2005).

Article
CAS
PubMed

Google Scholar

Demuro, A., Parker, I. & Stutzmann, G. E. Calcium signaling and amyloid toxicity in Alzheimer disease. J. Biol. Chem. 285, 12463–12468 (2010).

Article
CAS
PubMed
PubMed Central

Google Scholar

Norambuena, A. et al. A novel lysosome-to-mitochondria signaling pathway disrupted by amyloid-β oligomers. EMBO J. 37, e100241 (2018).

Article
PubMed
PubMed Central

Google Scholar

Reddy, P. H. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer’s disease. Exp. Neurol. 218, 286–292 (2009).

Article
CAS
PubMed
PubMed Central

Google Scholar

Wang, X. et al. Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease. Free Radic. Biol. Med 43, 1569–1573 (2007).

Article
CAS
PubMed

Google Scholar

Butterfield, D. A., Swomley, A. M. & Sultana, R. Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid. Redox Signal 19, 823–835 (2013).

Article
CAS
PubMed
PubMed Central

Google Scholar

Wilcox, K. C., Lacor, P. N., Pitt, J. & Klein, W. L. Aβ oligomer-induced synapse degeneration in Alzheimer’s disease. Cell Mol. Neurobiol. 31, 939–948 (2011).

Article
CAS
PubMed
PubMed Central

Google Scholar

Hardy, J. A. & Higgins, G. A. Alzheimer’s disease: the amyloid cascade hypothesis. Science 256, 184–185 (1992).

Article
CAS
PubMed

Google Scholar

Makin, S. The amyloid hypothesis on trial. Nature 559, S4–S7 (2018).

Article
CAS
PubMed

Google Scholar

Frisoni, G. B. et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat. Rev. Neurosci. 23, 53–66 (2022).

Article
CAS
PubMed

Google Scholar

Granzotto, A. & Sensi, S. L. Once upon a time, the Amyloid Cascade Hypothesis. Ageing Res. Rev. 93, 102161 (2024).

Article
CAS
PubMed

Google Scholar

Morris, G. P., Clark, I. A. & Vissel, B. Questions concerning the role of amyloid-beta in the definition, aetiology and diagnosis of Alzheimer’s disease. Acta Neuropathol. 136, 663–689 (2018).

Article
CAS
PubMed
PubMed Central

Google Scholar

Glass, D. J. & Arnold, S. E. Some evolutionary perspectives on Alzheimer’s disease pathogenesis and pathology. Alzheimers Dement. 8, 343–351 (2012).

Article
CAS
PubMed

Google Scholar

Roda, A. R. et al. Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease. Neural Regen. Res. 17, 1666–1674 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Zhang, H. et al. Interaction between Aβ and Tau in the Pathogenesis of Alzheimer’s Disease. Int J. Biol. Sci. 17, 2181–2192 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Bruni, A. C., Bernardi, L. & Gabelli, C. From beta amyloid to altered proteostasis in Alzheimer’s disease. Ageing Res. Rev. 64, 101126 (2020).

Article
CAS
PubMed

Google Scholar

Ossenkoppele, R., van der Kant, R. & Hansson, O. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726–734 (2022).

Article
CAS
PubMed

Google Scholar

Sinsky, J., Pichlerova, K. & Hanes, J. Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies. Int J. Mol. Sci. 22, 9207 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Wei, Y., Liu, M. & Wang, D. The propagation mechanisms of extracellular tau in Alzheimer’s disease. J. Neurol. 269, 1164–1181 (2022).

Article
PubMed

Google Scholar

Tang, Y., Zhang, D., Gong, X. & Zheng, J. A mechanistic survey of Alzheimer’s disease. Biophys. Chem. 281, 106735 (2022).

Article
CAS
PubMed

Google Scholar

Chong, F. P., Ng, K. Y., Koh, R. Y. & Chye, S. M. Tau Proteins and Tauopathies in Alzheimer’s Disease. Cell Mol. Neurobiol. 38, 965–980 (2018).

Article
CAS
PubMed

Google Scholar

Bjørklund, G., Aaseth, J., Dadar, M. & Chirumbolo, S. Molecular Targets in Alzheimer’s Disease. Mol. Neurobiol. 56, 7032–7044 (2019).

Article
PubMed

Google Scholar

Almansoub, H. et al. Tau Abnormalities and the Potential Therapy in Alzheimer’s Disease. J. Alzheimers Dis. 67, 13–33 (2019).

Article
PubMed

Google Scholar

Wu, X. L. et al. Tau-mediated Neurodegeneration and potential implications in diagnosis and treatment of Alzheimer’s Disease. Chin. Med. J. 130, 2978–2990 (2017).

Article
CAS
PubMed
PubMed Central

Google Scholar

Yin, X. et al. Dendritic/Post-synaptic Tau and Early Pathology of Alzheimer’s Disease. Front Mol. Neurosci. 14, 671779 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Amadoro, G., Latina, V., Corsetti, V. & Calissano, P. N-terminal tau truncation in the pathogenesis of Alzheimer’s disease (AD): Developing a novel diagnostic and therapeutic approach. Biochim Biophys. Acta Mol. Basis Dis. 1866, 165584 (2020).

Article
CAS
PubMed

Google Scholar

Novak, M., Kabat, J. & Wischik, C. M. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer’s disease paired helical filament. EMBO J. 12, 365–370 (1993).

Article
CAS
PubMed
PubMed Central

Google Scholar

Wang, J. Z., Grundke-Iqbal, I. & Iqbal, K. Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer’s disease. Nat. Med. 2, 871–875 (1996).

Article
CAS
PubMed

Google Scholar

Liu, K. et al. Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property. Biochim. Biophys. Acta 1862, 192–201 (2016).

Article
CAS
PubMed

Google Scholar

Luo, H. B. et al. SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc. Natl Acad. Sci. USA 111, 16586–16591 (2014).

Article
CAS
PubMed
PubMed Central

Google Scholar

Ray, W. J. & Buggia-Prevot, V. Novel Targets for Alzheimer’s Disease: A View Beyond Amyloid. Annu. Rev. Med. 72, 15–28 (2021).

Article
CAS
PubMed

Google Scholar

Sintini, I. et al. Longitudinal rates of atrophy and tau accumulation differ between the visual and language variants of atypical Alzheimer’s disease. Alzheimers Dement. 19, 4396–4406 (2023).

Article
PubMed

Google Scholar

Whitwell, J. L. et al. Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer’s disease. Alzheimers Dement. 14, 1005–1014 (2018).

Article
PubMed

Google Scholar

Weston, P. S. J. et al. Cortical tau is associated with microstructural imaging biomarkers of neurite density and dendritic complexity in Alzheimer’s disease. Alzheimers Dement. 19, 2750–2754 (2023).

Article
CAS
PubMed

Google Scholar

Sala Frigerio, C. & De Strooper, B. Alzheimer’s Disease Mechanisms and Emerging Roads to Novel Therapeutics. Annu. Rev. Neurosci. 39, 57–79 (2016).

Article
CAS
PubMed

Google Scholar

Leng, F. & Edison, P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat. Rev. Neurol. 17, 157–172 (2021).

Article
PubMed

Google Scholar

von Bernhardi, R., Eugenín-von Bernhardi, L. & Eugenín, J. Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci. 7, 124 (2015).

Balducci, C. & Forloni, G. Novel targets in Alzheimer’s disease: A special focus on microglia. Pharm. Res. 130, 402–413 (2018).

Article
CAS

Google Scholar

Hickman, S. E., Allison, E. K. & El Khoury, J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice. J. Neurosci. 28, 8354–8360 (2008).

Article
CAS
PubMed
PubMed Central

Google Scholar

Ferrari, C. & Sorbi, S. The complexity of Alzheimer’s disease: an evolving puzzle. Physiol. Rev. 101, 1047–1081 (2021).

Article
CAS
PubMed

Google Scholar

Venegas, C. et al. Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease. Nature 552, 355–361 (2017).

Article
CAS
PubMed

Google Scholar

Busche, M. A. & Hyman, B. T. Synergy between amyloid-β and tau in Alzheimer’s disease. Nat. Neurosci. 23, 1183–1193 (2020).

Article
CAS
PubMed

Google Scholar

Španić, E., Langer Horvat, L., Hof, P. R. & Šimić, G. Role of Microglial Cells in Alzheimer’s Disease Tau Propagation. Front. Aging Neurosci. 11, 271 (2019).

Article
PubMed
PubMed Central

Google Scholar

Sumsuzzman, D. M. et al. Microglia in Alzheimer’s Disease: A Favorable Cellular Target to Ameliorate Alzheimer’s Pathogenesis. Mediators Inflamm. 2022, 6052932 (2022).

Article
PubMed
PubMed Central

Google Scholar

Althafar, Z. M. Targeting Microglia in Alzheimer’s Disease: From Molecular Mechanisms to Potential Therapeutic Targets for Small Molecules. Molecules 27, 4124 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Heneka, M. T. ApoE4 makes microglia trem(2)bling. Neuron 111, 142–144 (2023).

Article
CAS
PubMed

Google Scholar

Guo, T. et al. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Mol. Neurodegener. 15, 40 (2020).

Article
PubMed
PubMed Central

Google Scholar

Liu, C. C. et al. Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer’s disease. Nat. Immunol. 24, 1854–1866 (2023).

Article
CAS
PubMed

Google Scholar

Self, W. K. & Holtzman, D. M. Emerging diagnostics and therapeutics for Alzheimer disease. Nat. Med. 29, 2187–2199 (2023).

Article
CAS
PubMed

Google Scholar

Zhang, W., Xiao, D., Mao, Q. & Xia, H. Role of neuroinflammation in neurodegeneration development. Signal Transduct. Target Ther. 8, 267 (2023).

Article
PubMed
PubMed Central

Google Scholar

Nouraeinejad, A. The Link Between COVID-19 and Alzheimer Disease Through Neuroinflammation. Clin. Med. Res. 21, 119–121 (2023).

Article
PubMed
PubMed Central

Google Scholar

Bello-Corral, L. et al. Implications of gut and oral microbiota in neuroinflammatory responses in Alzheimer’s disease. Life Sci. 333, 122132 (2023).

Article
CAS
PubMed

Google Scholar

Wong-Guerra, M., Calfio, C., Maccioni, R. B. & Rojo, L. E. Revisiting the neuroinflammation hypothesis in Alzheimer’s disease: a focus on the druggability of current targets. Front. Pharm. 14, 1161850 (2023).

Article
CAS

Google Scholar

Calsolaro, V. & Edison, P. Neuroinflammation in Alzheimer’s disease: Current evidence and future directions. Alzheimers Dement. 12, 719–732 (2016).

Article
PubMed

Google Scholar

Lecca, D. et al. Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis. Alzheimers Dement. 18, 2327–2340 (2022).

Article
CAS
PubMed

Google Scholar

Praticò, D. Oxidative stress hypothesis in Alzheimer’s disease: a reappraisal. Trends Pharm. Sci. 29, 609–615 (2008).

Article
PubMed

Google Scholar

Christen, Y. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 71, 621S–629S (2000).

Article
CAS
PubMed

Google Scholar

Markesbery, W. R. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic. Biol. Med. 23, 134–147 (1997).

Article
CAS
PubMed

Google Scholar

Miranda, S. et al. The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer’s disease. Prog. Neurobiol. 62, 633–648 (2000).

Article
CAS
PubMed

Google Scholar

Bai, R. et al. Oxidative stress: The core pathogenesis and mechanism of Alzheimer’s disease. Ageing Res. Rev. 77, 101619 (2022).

Article
CAS
PubMed

Google Scholar

Chen, Z. & Zhong, C. Oxidative stress in Alzheimer’s disease. Neurosci. Bull. 30, 271–281 (2014).

Article
CAS
PubMed
PubMed Central

Google Scholar

Rosini, M. et al. Oxidative stress in Alzheimer’s disease: are we connecting the dots? J. Med. Chem. 57, 2821–2831 (2014).

Article
CAS
PubMed

Google Scholar

Ferreira, M. E. et al. Oxidative Stress in Alzheimer’s Disease: Should We Keep Trying Antioxidant Therapies? Cell Mol. Neurobiol. 35, 595–614 (2015).

Article
CAS
PubMed

Google Scholar

Poprac, P. et al. Targeting Free Radicals in Oxidative Stress-Related Human Diseases. Trends Pharm. Sci. 38, 592–607 (2017).

Article
CAS
PubMed

Google Scholar

Perluigi, M., Di Domenico, F. & Butterfield, D. A. Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease. Physiol. Rev. 104, 103–197 (2024).

Article
CAS
PubMed

Google Scholar

Roy, R. G., Mandal, P. K. & Maroon, J. C. Oxidative Stress Occurs Prior to Amyloid Aβ Plaque Formation and Tau Phosphorylation in Alzheimer’s Disease: Role of Glutathione and Metal Ions. ACS Chem. Neurosci. 14, 2944–2954 (2023).

Article
CAS
PubMed

Google Scholar

Sanders, O. D., Rajagopal, L. & Rajagopal, J. A. The oxidatively damaged DNA and amyloid-β oligomer hypothesis of Alzheimer’s disease. Free Radic. Biol. Med. 179, 403–412 (2022).

Article
CAS
PubMed

Google Scholar

Chen, L. L. et al. The metal ion hypothesis of Alzheimer’s disease and the anti-neuroinflammatory effect of metal chelators. Bioorg. Chem. 131, 106301 (2023).

Article
CAS
PubMed

Google Scholar

Ayton, S., Lei, P. & Bush, A. I. Metallostasis in Alzheimer’s disease. Free Radic. Biol. Med. 62, 76–89 (2013).

Article
CAS
PubMed

Google Scholar

Sensi, S. L., Granzotto, A., Siotto, M. & Squitti, R. Copper and Zinc Dysregulation in Alzheimer’s Disease. Trends Pharm. Sci. 39, 1049–1063 (2018).

Article
CAS
PubMed

Google Scholar

D’Acunto, C. W. et al. Metallomics for Alzheimer’s disease treatment: Use of new generation of chelators combining metal-cation binding and transport properties. Eur. J. Med. Chem. 150, 140–155 (2018).

Article
PubMed

Google Scholar

Caraci, F., Nicoletti, F. & Copani, A. Metabotropic glutamate receptors: the potential for therapeutic applications in Alzheimer’s disease. Curr. Opin. Pharm. 38, 1–7 (2018).

Article
CAS

Google Scholar

Sharma, P. et al. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies. Prog. Neurobiol. 174, 53–89 (2019).

Article
CAS
PubMed

Google Scholar

Zhong, W. et al. Pathogenesis of sporadic Alzheimer’s disease by deficiency of NMDA receptor subunit GluN3A. Alzheimers Dement. 18, 222–239 (2022).

Article
CAS
PubMed

Google Scholar

Verma, M., Lizama, B. N. & Chu, C. T. Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration. Transl. Neurodegener. 11, 3 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Granzotto, A., Canzoniero, L. M. T. & Sensi, S. L. A Neurotoxic Ménage-à-trois: Glutamate, Calcium, and Zinc in the Excitotoxic Cascade. Front. Mol. Neurosci. 13, 600089 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Bi, D., Wen, L., Wu, Z. & Shen, Y. GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer’s disease. Alzheimers Dement. 16, 1312–1329 (2020).

Article
PubMed

Google Scholar

Liu, S. et al. Gut Microbiota and Dysbiosis in Alzheimer’s Disease: Implications for Pathogenesis and Treatment. Mol. Neurobiol. 57, 5026–5043 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Bulgart, H. R., Neczypor, E. W., Wold, L. E. & Mackos, A. R. Microbial involvement in Alzheimer disease development and progression. Mol. Neurodegener. 15, 42 (2020).

Article
PubMed
PubMed Central

Google Scholar

La Rosa, F. et al. The Gut-Brain Axis in Alzheimer’s Disease and Omega-3. A Critical Overview of Clinical Trials. Nutrients 10, 1267 (2018).

Article
PubMed
PubMed Central

Google Scholar

Hu, X., Wang, T. & Jin, F. Alzheimer’s disease and gut microbiota. Sci. China Life Sci. 59, 1006–1023 (2016).

Article
CAS
PubMed

Google Scholar

Sochocka, M. et al. The Gut Microbiome Alterations and Inflammation-Driven Pathogenesis of Alzheimer’s Disease-a Critical Review. Mol. Neurobiol. 56, 1841–1851 (2019).

Article
CAS
PubMed

Google Scholar

Megur, A., Baltriukienė, D., Bukelskienė, V. & Burokas, A. The Microbiota-Gut-Brain Axis and Alzheimer’s Disease: Neuroinflammation Is to Blame? Nutrients 13, 37 (2020).

Article
PubMed
PubMed Central

Google Scholar

Ferreiro, A. L. et al. Gut microbiome composition may be an indicator of preclinical Alzheimer’s disease. Sci. Transl. Med. 15, eabo2984 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Zhang, X.-W., Zhu, X.-X., Tang, D.-S. & Lu, J.-H. Targeting autophagy in Alzheimer’s disease: Animal models and mechanisms. Zool. Res. 44, 1132–1145 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Aman, Y. et al. Autophagy in healthy aging and disease. Nat. Aging 1, 634–650 (2021).

Article
PubMed
PubMed Central

Google Scholar

Eshraghi, M. et al. Enhancing autophagy in Alzheimer’s disease through drug repositioning. Pharm. Ther. 237, 108171 (2022).

Article
CAS

Google Scholar

Kaushik, S. & Cuervo, A. M. The coming of age of chaperone-mediated autophagy. Nat. Rev. Mol. Cell Biol. 19, 365–381 (2018).

Article
CAS
PubMed
PubMed Central

Google Scholar

Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)(1). Autophagy 17, 1–382 (2021).

Article
PubMed
PubMed Central

Google Scholar

Nedelsky, N. B., Todd, P. K. & Taylor, J. P. Autophagy and the ubiquitin-proteasome system: Collaborators in neuroprotection. Biochim Biophys. Acta 1782, 691–699 (2008).

Article
CAS
PubMed
PubMed Central

Google Scholar

Dong, Z. & Cui, H. The Autophagy-Lysosomal Pathways and Their Emerging Roles in Modulating Proteostasis in Tumors. Cells 8, 4 (2018).

Article
PubMed
PubMed Central

Google Scholar

Deng, Z. et al. Pharmacological modulation of autophagy for Alzheimer’s disease therapy: Opportunities and obstacles. Acta Pharm. Sin. B 12, 1688–1706 (2022).

Article
CAS
PubMed

Google Scholar

Iranpour, M. et al. Apoptosis, autophagy and unfolded protein response pathways in Arbovirus replication and pathogenesis. Expert Rev. Mol. Med. 18, e1 (2016).

Article
PubMed
PubMed Central

Google Scholar

Nixon, R. A. The role of autophagy in neurodegenerative disease. Nat. Med. 19, 983–997 (2013).

Article
CAS
PubMed

Google Scholar

Yu, W. H. et al. Macroautophagy—a novel β-amyloid peptide-generating pathway activated in Alzheimer’s disease. J. Cell Biol. 171, 87–98 (2005).

Article
CAS
PubMed
PubMed Central

Google Scholar

Kerr, J. S. et al. Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms. Trends Neurosci. 40, 151–166 (2017).

Article
CAS
PubMed
PubMed Central

Google Scholar

Bourdenx, M. et al. Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome. Cell 184, 2696–2714.e2625 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Wang, Z. et al. Microglial autophagy in Alzheimer’s disease and Parkinson’s disease. Front. Aging Neurosci. 14, 1065183 (2023).

Article
PubMed
PubMed Central

Google Scholar

Litwiniuk, A., Juszczak, G. R., Stankiewicz, A. M. & Urbańska, K. The role of glial autophagy in Alzheimer’s disease. Mol. Psychiatry 28, 4528–4539 (2023).

Article
CAS
PubMed

Google Scholar

Zhang, Z., Yang, X., Song, Y.-Q. & Tu, J. Autophagy in Alzheimer’s disease pathogenesis: Therapeutic potential and future perspectives. Ageing Res. Rev. 72, 101464 (2021).

Article
CAS
PubMed

Google Scholar

Chandra, S. & Pahan, K. Gemfibrozil, a Lipid-Lowering Drug, Lowers Amyloid Plaque Pathology and Enhances Memory in a Mouse Model of Alzheimer’s Disease via Peroxisome Proliferator-Activated Receptor α. J. Alzheimers Dis. Rep. 3, 149–168 (2019).

Article
PubMed
PubMed Central

Google Scholar

Luo, R. et al. Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model. Autophagy 16, 52–69 (2020).

Article
CAS
PubMed

Google Scholar

Zheng, Y. et al. Inflammatory signaling pathways in the treatment of Alzheimer’s disease with inhibitors, natural products and metabolites (Review). Int. J. Mol. Med. 52, 111 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Thakur, S. et al. Neuroinflammation in Alzheimer’s Disease: Current Progress in Molecular Signaling and Therapeutics. Inflammation 46, 1–17 (2023).

Article
CAS
PubMed

Google Scholar

Dhapola, R. et al. Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer’s disease. Inflammopharmacology 29, 1669–1681 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Li, Z. et al. Targeting protein kinases for the treatment of Alzheimer’s disease: Recent progress and future perspectives. Eur. J. Med. Chem. 261, 115817 (2023).

Article
CAS
PubMed

Google Scholar

Huang, R. et al. Whole-plant foods and their macromolecules: untapped approaches to modulate neuroinflammation in Alzheimer’s disease. Crit. Rev. Food Sci. Nutr. 63, 2388–2406 (2023).

Article
CAS
PubMed

Google Scholar

Seo, E.-J., Fischer, N. & Efferth, T. J. P. Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer’s disease. Pharm. Res. 129, 262–273 (2018).

Article
CAS

Google Scholar

Morgan, M. J. & Liu, Z. G. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 21, 103–115 (2011).

Article
CAS
PubMed

Google Scholar

Zhao, K. et al. The miR-25802/KLF4/NF-κB signaling axis regulates microglia-mediated neuroinflammation in Alzheimer’s disease. Brain Behav. Immun. 118, 31–48 (2024).

Article
CAS
PubMed

Google Scholar

Blevins, H. M., Xu, Y., Biby, S. & Zhang, S. The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases. Front Aging Neurosci. 14, 879021 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Naeem, A. et al. MCC950 reduces autophagy and improves cognitive function by inhibiting NLRP3-dependent neuroinflammation in a rat model of Alzheimer’s disease. Brain Behav. Immun. 116, 70–84 (2024).

Article
CAS
PubMed

Google Scholar

Terzioglu, G. & Young-Pearse, T. L. Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease. Mol. Neurodegener. 18, 89 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Moonen, S. et al. Pyroptosis in Alzheimer’s disease: cell type-specific activation in microglia, astrocytes and neurons. Acta Neuropathol. 145, 175–195 (2023).

Article
CAS
PubMed

Google Scholar

Wang, C. et al. Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy. Nat. Commun. 13, 1969 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Dutta, D. et al. Tau fibrils induce glial inflammation and neuropathology via TLR2 in Alzheimer’s disease-related mouse models. J. Clin. Invest. 133, e161987 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Ising, C. et al. NLRP3 inflammasome activation drives tau pathology. Nature 575, 669–673 (2019).

Article
CAS
PubMed
PubMed Central

Google Scholar

Xie, X. et al. Activation of innate immune cGAS-STING pathway contributes to Alzheimer’s pathogenesis in 5×FAD mice. Nat. Aging 3, 202–212 (2023).

Article
CAS
PubMed

Google Scholar

Huang, Y. et al. Mechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders. Mol. Neurodegener. 18, 79 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Jorfi, M., Maaser-Hecker, A. & Tanzi, R. E. The neuroimmune axis of Alzheimer’s disease. Genome Med. 15, 6 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Dionisio-Santos, D. A., Olschowka, J. A. & O’Banion, M. K. Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease. J. Neuroinflamm. 16, 74 (2019).

Article

Google Scholar

Jorfi, M. et al. Infiltrating CD8+ T cells exacerbate Alzheimer’s disease pathology in a 3D human neuroimmune axis model. Nat. Neurosci. 26, 1489–1504 (2023).

Unger, M. S. et al. CD8(+) T-cells infiltrate Alzheimer’s disease brains and regulate neuronal- and synapse-related gene expression in APP-PS1 transgenic mice. Brain Behav. Immun. 89, 67–86 (2020).

Article
CAS
PubMed

Google Scholar

Wang, Y. et al. TREM2 ameliorates neuroinflammatory response and cognitive impairment via PI3K/AKT/FoxO3a signaling pathway in Alzheimer’s disease mice. Aging 12, 20862–20879 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Zhong, L. et al. TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1q during neurodegeneration. Immunity 56, 1794–1808.e8 (2023).

Article
CAS
PubMed

Google Scholar

Cao, M., Luo, X., Wu, K. & He, X. Targeting lysosomes in human disease: from basic research to clinical applications. Signal Transduct. Target Ther. 6, 379 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Hu, Y. B., Dammer, E. B., Ren, R. J. & Wang, G. The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration. Transl. Neurodegener. 4, 18 (2015).

Article
PubMed
PubMed Central

Google Scholar

Orr, M. E. & Oddo, S. Autophagic/lysosomal dysfunction in Alzheimer’s disease. Alzheimers Res. Ther. 5, 53 (2013).

Article
PubMed
PubMed Central

Google Scholar

Xiong, J. & Zhu, M. X. Regulation of lysosomal ion homeostasis by channels and transporters. Sci. China Life Sci. 59, 777–791 (2016).

Article
CAS
PubMed
PubMed Central

Google Scholar

Lo, C. H. & Zeng, J. Defective lysosomal acidification: a new prognostic marker and therapeutic target for neurodegenerative diseases. Transl. Neurodegener. 12, 29 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Lee, J. H. et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141, 1146–1158 (2010).

Article
CAS
PubMed
PubMed Central

Google Scholar

Zhang, X. et al. A role for presenilins in autophagy revisited: normal acidification of lysosomes in cells lacking PSEN1 and PSEN2. J. Neurosci. 32, 8633–8648 (2012).

Article
CAS
PubMed
PubMed Central

Google Scholar

Coen, K. et al. Lysosomal calcium homeostasis defects, not proton pump defects, cause endo-lysosomal dysfunction in PSEN-deficient cells. J. Cell Biol. 198, 23–35 (2012).

Article
CAS
PubMed
PubMed Central

Google Scholar

Lee, J. H. et al. Presenilin 1 Maintains Lysosomal Ca(2+) Homeostasis via TRPML1 by Regulating vATPase-Mediated Lysosome Acidification. Cell Rep. 12, 1430–1444 (2015).

Article
CAS
PubMed
PubMed Central

Google Scholar

Tong, B. C. et al. Lysosomal TPCN (two pore segment channel) inhibition ameliorates beta-amyloid pathology and mitigates memory impairment in Alzheimer disease. Autophagy 18, 624–642 (2022).

Article
CAS
PubMed

Google Scholar

Im, E. et al. Lysosomal dysfunction in Down syndrome and Alzheimer mouse models is caused by v-ATPase inhibition by Tyr(682)-phosphorylated APP βCTF. Sci. Adv. 9, eadg1925 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Dietschy, J. M. & Turley, S. D. Cholesterol metabolism in the brain. Curr. Opin. Lipido 12, 105–112 (2001).

Article
CAS

Google Scholar

Ahmed, H. et al. Brain cholesterol and Alzheimer’s disease: challenges and opportunities in probe and drug development. Brain 147, 1622–1635 (2024).

Article
PubMed

Google Scholar

Qian, L., Chai, A. B., Gelissen, I. C. & Brown, A. J. J. Eo. N. T. Balancing cholesterol in the brain: From synthesis to disposal. Explor Neuroprot. Ther. 2, 1–27 (2022).

Article

Google Scholar

Li, D., Zhang, J. & Liu, Q. Brain cell type-specific cholesterol metabolism and implications for learning and memory. Trends Neurosci. 45, 401–414 (2022).

Article
CAS
PubMed

Google Scholar

Feringa, F. M. & van der Kant, R. Cholesterol and Alzheimer’s Disease; From Risk Genes to Pathological Effects. Front Aging Neurosci. 13, 690372 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Wolozin, B. Cholesterol and the biology of Alzheimer’s disease. Neuron 41, 7–10 (2004).

Article
CAS
PubMed

Google Scholar

Wang, H. et al. Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Proc. Natl Acad. Sci. USA 118, e2102191118 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Huang, S. et al. Chimeric cerebral organoids reveal the essentials of neuronal and astrocytic APOE4 for Alzheimer’s tau pathology. Signal Transduct. Target Ther. 7, 176 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Litvinchuk, A. et al. Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist. Neuron 112, 384–403.e8 (2024).

Article
CAS
PubMed

Google Scholar

de Dios, C. et al. Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis. Transl. Neurodegener. 12, 10 (2023).

Article
PubMed
PubMed Central

Google Scholar

Gowda, P., Reddy, P. H. & Kumar, S. Deregulated mitochondrial microRNAs in Alzheimer’s disease: Focus on synapse and mitochondria. Ageing Res. Rev. 73, 101529 (2022).

Article
CAS
PubMed

Google Scholar

Wang, W. et al. Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances. Mol. Neurodegener. 15, 30 (2020).

Article
PubMed
PubMed Central

Google Scholar

Kapogiannis, D. & Mattson, M. P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer’s disease. Lancet Neurol. 10, 187–198 (2011).

Article
CAS
PubMed

Google Scholar

Godoy, J. A. et al. Signaling pathway cross talk in Alzheimer’s disease. Cell Commun. Signal 12, 23 (2014).

Article
PubMed
PubMed Central

Google Scholar

Eckert, A., Schmitt, K. & Götz, J. Mitochondrial dysfunction – the beginning of the end in Alzheimer’s disease? Separate and synergistic modes of tau and amyloid-β toxicity. Alzheimers Res. Ther. 3, 15 (2011).

Article
CAS
PubMed
PubMed Central

Google Scholar

Lustbader, J. W. et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science 304, 448–452 (2004).

Article
CAS
PubMed

Google Scholar

Ye, Z. et al. Aβ-binding with alcohol dehydrogenase drives Alzheimer’s disease pathogenesis: A review. Int. J. Biol. Macromol. 264, 130580 (2024).

Article
CAS
PubMed

Google Scholar

Misrani, A., Tabassum, S. & Yang, L. Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease. Front. Aging Neurosci. 13, 57 (2021).

De Nicolo, B., Cataldi-Stagetti, E., Diquigiovanni, C. & Bonora, E. Calcium and Reactive Oxygen Species Signaling Interplays in Cardiac Physiology and Pathologies. Antioxidants 12, 353 (2023).

Article
PubMed
PubMed Central

Google Scholar

Bezprozvanny, I. & Mattson, M. P. Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends Neurosci. 31, 454–463 (2008).

Article
CAS
PubMed
PubMed Central

Google Scholar

Resende, R., Ferreiro, E., Pereira, C. & Resende de Oliveira, C. Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience 155, 725–737 (2008).

Article
CAS
PubMed

Google Scholar

Calvo-Rodriguez, M. & Bacskai, B. J. High mitochondrial calcium levels precede neuronal death in vivo in Alzheimer’s disease. Cell Stress 4, 187–190 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Calvo-Rodriguez, M. et al. Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer’s disease. Nat. Commun. 11, 2146 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Du, H. & ShiDu Yan, S. Unlocking the Door to Neuronal Woes in Alzheimer’s Disease: Aβ and Mitochondrial Permeability Transition Pore. Pharmaceuticals 3, 1936–1948 (2010).

Article
CAS
PubMed
PubMed Central

Google Scholar

Calvo-Rodriguez, M. & Bacskai, B. J. Mitochondria and Calcium in Alzheimer’s Disease: From Cell Signaling to Neuronal Cell Death. Trends Neurosci. 44, 136–151 (2021).

Article
CAS
PubMed

Google Scholar

Millecamps, S. & Julien, J. P. Axonal transport deficits and neurodegenerative diseases. Nat. Rev. Neurosci. 14, 161–176 (2013).

Article
CAS
PubMed

Google Scholar

Chen, W., Zhao, H. & Li, Y. Mitochondrial dynamics in health and disease: mechanisms and potential targets. Signal Transduct. Target Ther. 8, 333 (2023).

Article
PubMed
PubMed Central

Google Scholar

Cho, D. H. et al. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 324, 102–105 (2009).

Article
CAS
PubMed
PubMed Central

Google Scholar

Bossy, B. et al. S-Nitrosylation of DRP1 does not affect enzymatic activity and is not specific to Alzheimer’s disease. J. Alzheimers Dis. 20 (Suppl 2), S513–526 (2010).

Article
PubMed
PubMed Central

Google Scholar

Flannery, P. J. & Trushina, E. Mitochondrial dynamics and transport in Alzheimer’s disease. Mol. Cell Neurosci. 98, 109–120 (2019).

Article
CAS
PubMed
PubMed Central

Google Scholar

Pradeepkiran, J. A. & Reddy, P. H. Defective mitophagy in Alzheimer’s disease. Ageing Res. Rev. 64, 101191 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

John, A. & Reddy, P. H. Synaptic basis of Alzheimer’s disease: Focus on synaptic amyloid beta, P-tau and mitochondria. Ageing Res. Rev. 65, 101208 (2021).

Article
CAS
PubMed

Google Scholar

Li, X. et al. Molecular mechanisms of mitophagy and its roles in neurodegenerative diseases. Pharm. Res. 163, 105240 (2021).

Article
CAS

Google Scholar

Zeng, K. et al. Defective mitophagy and the etiopathogenesis of Alzheimer’s disease. Transl. Neurodegener. 11, 32 (2022).

Article
PubMed
PubMed Central

Google Scholar

Mary, A., Eysert, F., Checler, F. & Chami, M. Mitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches. Mol. Psychiatry 28, 202–216 (2023).

Article
CAS
PubMed

Google Scholar

Webber, E. K., Fivaz, M., Stutzmann, G. E. & Griffioen, G. Cytosolic calcium: Judge, jury and executioner of neurodegeneration in Alzheimer’s disease and beyond. Alzheimers Dement. 19, 3701–3717 (2023).

Article
CAS
PubMed

Google Scholar

McDaid, J., Mustaly-Kalimi, S. & Stutzmann, G. E. Ca(2+) Dyshomeostasis Disrupts Neuronal and Synaptic Function in Alzheimer’s Disease. Cells 9, 2655 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Pedriali, G. et al. Regulation of Endoplasmic Reticulum-Mitochondria Ca(2+) Transfer and Its Importance for Anti-Cancer Therapies. Front. Oncol. 7, 180 (2017).

Article
PubMed
PubMed Central

Google Scholar

Kawamoto, E. M., Vivar, C. & Camandola, S. Physiology and pathology of calcium signaling in the brain. Front. Pharm. 3, 61 (2012).

Article

Google Scholar

Madreiter-Sokolowski, C. T., Thomas, C. & Ristow, M. Interrelation between ROS and Ca(2+) in aging and age-related diseases. Redox Biol. 36, 101678 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Baracaldo-Santamaría, D. et al. Role of Calcium Modulation in the Pathophysiology and Treatment of Alzheimer’s Disease. Int. J. Mol. Sci. 24, 9067 (2023).

Article
PubMed
PubMed Central

Google Scholar

Mochida, S. Calcium Channels and Calcium-Binding Proteins. Int J. Mol. Sci. 24, 14257 (2023).

Article
PubMed
PubMed Central

Google Scholar

Mattson, M. P. Calcium and neurodegeneration. Aging Cell 6, 337–350 (2007).

Article
CAS
PubMed

Google Scholar

Bezprozvanny, I. Calcium signaling and neurodegenerative diseases. Trends Mol. Med. 15, 89–100 (2009).

Article
CAS
PubMed
PubMed Central

Google Scholar

Giorgi, C. et al. Calcium Dynamics as a Machine for Decoding Signals. Trends Cell Biol. 28, 258–273 (2018).

Article
CAS
PubMed

Google Scholar

Smajilovic, S. & Tfelt-Hansen, J. Calcium acts as a first messenger through the calcium-sensing receptor in the cardiovascular system. Cardiovasc. Res. 75, 457–467 (2007).

Article
CAS
PubMed

Google Scholar

Ozcan, L. & Tabas, I. Calcium signalling and ER stress in insulin resistance and atherosclerosis. J. Intern. Med. 280, 457–464 (2016).

Article
CAS
PubMed
PubMed Central

Google Scholar

Crossley, C. A., Rajani, V. & Yuan, Q. Modulation of L-type calcium channels in Alzheimer’s disease: A potential therapeutic target. Comput Struct. Biotechnol. J. 21, 11–20 (2023).

Article
CAS
PubMed

Google Scholar

Anekonda, T. S. et al. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer’s disease. Neurobiol. Dis. 41, 62–70 (2011).

Article
CAS
PubMed

Google Scholar

Tu, S., Okamoto, S., Lipton, S. A. & Xu, H. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease. Mol. Neurodegener. 9, 48 (2014).

Article
PubMed
PubMed Central

Google Scholar

Li, S. & Stern, A. M. Bioactive human Alzheimer brain soluble Aβ: pathophysiology and therapeutic opportunities. Mol. Psychiatry 27, 3182–3191 (2022).

Article
PubMed

Google Scholar

Uddin, M. S., Yu, W. S. & Lim, L. W. Exploring ER stress response in cellular aging and neuroinflammation in Alzheimer’s disease. Ageing Res. Rev. 70, 101417 (2021).

Article
CAS
PubMed

Google Scholar

Carvalho, E. J., Stathopulos, P. B. & Madesh, M. Regulation of Ca(2+) exchanges and signaling in mitochondria. Curr. Opin. Physiol. 17, 197–206 (2020).

Article
PubMed
PubMed Central

Google Scholar

Liu, Y. & Zhu, X. Endoplasmic reticulum-mitochondria tethering in neurodegenerative diseases. Transl. Neurodegener. 6, 21 (2017).

Article
PubMed
PubMed Central

Google Scholar

Liu, J. & Yang, J. Mitochondria-associated membranes: A hub for neurodegenerative diseases. Biomed. Pharmacother. 149, 112890 (2022).

Article
CAS
PubMed

Google Scholar

Hedskog, L. et al. Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer’s disease and related models. Proc. Natl Acad. Sci. USA 110, 7916–7921 (2013).

Article
CAS
PubMed
PubMed Central

Google Scholar

Area-Gomez, E. et al. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J. 31, 4106–4123 (2012).

Article
CAS
PubMed
PubMed Central

Google Scholar

Yu, W., Jin, H. & Huang, Y. Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer’s disease. Clin. Sci. 135, 109–126 (2021).

Article
CAS

Google Scholar

Mustaly-Kalimi, S. et al. Protein mishandling and impaired lysosomal proteolysis generated through calcium dysregulation in Alzheimer’s disease. Proc. Natl Acad. Sci. USA 119, e2211999119 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

De Felice, F. G., Gonçalves, R. A. & Ferreira, S. T. Impaired insulin signalling and allostatic load in Alzheimer disease. Nat. Rev. Neurosci. 23, 215–230 (2022).

Article
PubMed

Google Scholar

Nowell, J., Blunt, E. & Edison, P. Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease. Mol. Psychiatry 28, 217–229 (2023).

Article
CAS
PubMed

Google Scholar

Correia, S. C. et al. Insulin-resistant brain state: the culprit in sporadic Alzheimer’s disease? Ageing Res. Rev. 10, 264–273 (2011).

Article
CAS
PubMed
PubMed Central

Google Scholar

Nowell, J., Blunt, E., Gupta, D. & Edison, P. Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease. Ageing Res. Rev. 89, 101979 (2023).

Article
CAS
PubMed

Google Scholar

Kellar, D. & Craft, S. Brain insulin resistance in Alzheimer’s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 19, 758–766 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Steen, E. et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease–is this type 3 diabetes? J. Alzheimers Dis. 7, 63–80 (2005).

Article
CAS
PubMed

Google Scholar

Gabbouj, S. et al. Altered Insulin Signaling in Alzheimer’s Disease Brain – Special Emphasis on PI3K-Akt Pathway. Front. Neurosci. 13, 629 (2019).

Article
PubMed
PubMed Central

Google Scholar

Hooper, C., Killick, R. & Lovestone, S. The GSK3 hypothesis of Alzheimer’s disease. J. Neurochem. 104, 1433–1439 (2008).

Article
CAS
PubMed
PubMed Central

Google Scholar

Kim, B. & Feldman, E. L. Insulin resistance in the nervous system. Trends Endocrinol. Metab. 23, 133–141 (2012).

Article
CAS
PubMed
PubMed Central

Google Scholar

Querfurth, H. & Lee, H. K. Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration. Mol. Neurodegener. 16, 44 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Bomfim, T. R. et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Aβ oligomers. J. Clin. Invest. 122, 1339–1353 (2012).

Article
CAS
PubMed
PubMed Central

Google Scholar

Nagahara, A. H. & Tuszynski, M. H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat. Rev. Drug Discov. 10, 209–219 (2011).

Article
CAS
PubMed

Google Scholar

Kim, J., He, M. J., Widmann, A. K. & Lee, F. S. The role of neurotrophic factors in novel, rapid psychiatric treatments. Neuropsychopharmacology 49, 227–245 (2024).

Article
CAS
PubMed

Google Scholar

Pentz, R. et al. The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease. Mol. Psychiatry 26, 6023–6037 (2021).

Article
CAS
PubMed

Google Scholar

Triaca, V. et al. NGF controls APP cleavage by downregulating APP phosphorylation at Thr668: relevance for Alzheimer’s disease. Aging Cell 15, 661–672 (2016).

Article
CAS
PubMed
PubMed Central

Google Scholar

Xhima, K. et al. Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies. Brain 145, 2806–2822 (2022).

Article
PubMed

Google Scholar

Ding, X. W. et al. Nerve growth factor in metabolic complications and Alzheimer’s disease: Physiology and therapeutic potential. Biochim. Biophys. Acta Mol. Basis Dis. 1866, 165858 (2020).

Article
CAS
PubMed

Google Scholar

Phillips, H. S. et al. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron 7, 695–702 (1991).

Article
CAS
PubMed

Google Scholar

Xiang, J. et al. Delta-secretase-cleaved Tau antagonizes TrkB neurotrophic signalings, mediating Alzheimer’s disease pathologies. Proc. Natl Acad. Sci. USA 116, 9094–9102 (2019).

Article
CAS
PubMed
PubMed Central

Google Scholar

Wu, Z. et al. Neurotrophic signaling deficiency exacerbates environmental risks for Alzheimer’s disease pathogenesis. Proc. Natl Acad. Sci. USA 118, e2100986118 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Wang, Z. H. et al. Deficiency in BDNF/TrkB Neurotrophic Activity Stimulates δ-Secretase by Upregulating C/EBPβ in Alzheimer’s Disease. Cell Rep. 28, 655–669.e5 (2019).

Article
CAS
PubMed
PubMed Central

Google Scholar

Matrone, C. et al. NGF and BDNF signaling control amyloidogenic route and Abeta production in hippocampal neurons. Proc. Natl Acad. Sci. USA 105, 13139–13144 (2008).

Article
CAS
PubMed
PubMed Central

Google Scholar

Tong, L., Balazs, R., Thornton, P. L. & Cotman, C. W. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J. Neurosci. 24, 6799–6809 (2004).

Article
CAS
PubMed
PubMed Central

Google Scholar

Wang, W. et al. Microglial repopulation reverses cognitive and synaptic deficits in an Alzheimer’s disease model by restoring BDNF signaling. Brain Behav. Immun. 113, 275–288 (2023).

Article
CAS
PubMed

Google Scholar

Alkhalifa, A. E. et al. Blood-Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies. Int J. Mol. Sci. 24, 16288 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Nehra, G., Bauer, B. & Hartz, A. M. S. Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance. Pharm. Ther. 234, 108119 (2022).

Article
CAS

Google Scholar

Chen, L. et al. Opportunities and challenges in delivering biologics for Alzheimer’s disease by low-intensity ultrasound. Adv. Drug Deliv. Rev. 189, 114517 (2022).

Article
CAS
PubMed

Google Scholar

Zlokovic, B. V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat. Rev. Neurosci. 12, 723–738 (2011).

Article
CAS
PubMed
PubMed Central

Google Scholar

Bell, A. H., Miller, S. L., Castillo-Melendez, M. & Malhotra, A. The Neurovascular Unit: Effects of Brain Insults During the Perinatal Period. Front. Neurosci. 13, 1452 (2019).

Article
PubMed

Google Scholar

Montagne, A., Zhao, Z. & Zlokovic, B. V. Alzheimer’s disease: A matter of blood-brain barrier dysfunction? J. Exp. Med. 214, 3151–3169 (2017).

Article
CAS
PubMed
PubMed Central

Google Scholar

Pan, Y. & Nicolazzo, J. A. Impact of aging, Alzheimer’s disease and Parkinson’s disease on the blood-brain barrier transport of therapeutics. Adv. Drug Deliv. Rev. 135, 62–74 (2018).

Article
CAS
PubMed

Google Scholar

Zenaro, E., Piacentino, G. & Constantin, G. The blood-brain barrier in Alzheimer’s disease. Neurobiol. Dis. 107, 41–56 (2017).

Article
CAS
PubMed
PubMed Central

Google Scholar

Erickson, M. A. & Banks, W. A. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer’s disease. J. Cereb. Blood Flow. Metab. 33, 1500–1513, (2013).

Article
CAS
PubMed
PubMed Central

Google Scholar

Winkler, E. A. et al. GLUT1 reductions exacerbate Alzheimer’s disease vasculo-neuronal dysfunction and degeneration. Nat. Neurosci. 18, 521–530 (2015).

Article
CAS
PubMed
PubMed Central

Google Scholar

Jack, C. R. et al. NIA‐AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14, 535–562 (2018).

Article
PubMed

Google Scholar

Mahaman, Y. A. R. et al. Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention. Ageing Res. Rev. 74, 101544 (2022).

Article
CAS
PubMed

Google Scholar

Scheltens, P. et al. Alzheimer’s disease. Lancet 397, 1577–1590 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Klyucherev, T. O. et al. Advances in the development of new biomarkers for Alzheimer’s disease. Transl. Neurodegener. 11, 25 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Brown RK, B. N.Wong, K. K., Minoshima, S. & Frey, K. A. Brain PET in suspected dementia: patterns of altered FDG metabolism. Radiographics 34, 684–701 (2014).

Article
PubMed

Google Scholar

van Oostveen, W. M. & de Lange, E. C. M. Imaging Techniques in Alzheimer’s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring. Int J. Mol. Sci. 22, 2110 (2021).

Article
PubMed
PubMed Central

Google Scholar

Andersen, E. et al. Diagnostic biomarkers in Alzheimer’s disease. Biomark. Neuropsychiatry 5, 100041 (2021).

Article

Google Scholar

Olsson, B. et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 15, 673–684 (2016).

Article
CAS
PubMed

Google Scholar

Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 13, 614–629 (2014).

Article
PubMed

Google Scholar

Bucci, M., Chiotis, K. & Nordberg, A. Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol. Psychiatry 26, 5888–5898 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Jia, J. et al. Biomarker Changes during 20 Years Preceding Alzheimer’s Disease. N. Engl. J. Med. 390, 712–722 (2024).

Article
CAS
PubMed

Google Scholar

Zhao, A. et al. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer’s disease. J. Clin. Invest. 132, e158708 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Zetterberg, H. Biofluid‐based biomarkers for Alzheimer’s disease–related pathologies: An update and synthesis of the literature. Alzheimers Dement. 18, 1687–1693 (2022).

Article
PubMed

Google Scholar

Carter, S. F. et al. Astrocyte Biomarkers in Alzheimer’s Disease. Trends Mol. Med. 25, 77–95 (2019).

Article
CAS
PubMed

Google Scholar

Kumar, A. et al. Amyloid and Tau in Alzheimer’s Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger? Am. J. Psychiatry 178, 1014–1025 (2021).

Article
PubMed

Google Scholar

Nation, D. A. et al. Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat. Med. 25, 270–276 (2019).

Article
CAS
PubMed
PubMed Central

Google Scholar

Wong, M. W. et al. Dysregulation of lipids in Alzheimer’s disease and their role as potential biomarkers. Alzheimers Dement. 13, 810–827 (2017).

Article
PubMed

Google Scholar

Paciotti, S. et al. Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer’s disease continuum. Alzheimers Res. Ther. 15, 124 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Yuyama, K. et al. Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer’s disease pathogenesis. Brain 147, 627–636 (2023).

Article
PubMed Central

Google Scholar

Chatterjee, M. et al. C1q is increased in cerebrospinal fluid‐derived extracellular vesicles in Alzheimer’s disease: A multi‐cohort proteomics and immuno‐assay validation study. Alzheimers Dement. 19, 4828–4840 (2023).

Article
CAS
PubMed

Google Scholar

Blennow, K. et al. The potential clinical value of plasma biomarkers in Alzheimer’s disease. Alzheimers Dement. 19, 5805–5816 (2023).

Article
CAS
PubMed

Google Scholar

Rani, S. et al. Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease. Cell Mol. Neurobiol. 43, 2491–2523 (2023).

Article
PubMed

Google Scholar

Hu, S., Yang, C. & Luo, H. Current trends in blood biomarker detection and imaging for Alzheimer’s disease. Biosens. Bioelectron. 210, 114278 (2022).

Article
CAS
PubMed

Google Scholar

Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 21, 66–77 (2022).

Article
CAS
PubMed

Google Scholar

Blennow, K. & Zetterberg, H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J. Intern. Med. 284, 643–663 (2018).

Article
CAS
PubMed

Google Scholar

Jiang, Y. et al. A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer’s disease across ethnic groups. Alzheimers Dement. 20, 2000–2015 (2024).

Article
PubMed
PubMed Central

Google Scholar

Valenza, M. & Scuderi, C. How useful are biomarkers for the diagnosis of Alzheimer’s disease and especially for its therapy? Neural Regen. Res. 17, 2205–2207 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Schindler, S. E. & Karikari, T. K. Comorbidities confound Alzheimer’s blood tests. Nat. Med. 28, 1349–1351 (2022).

Article
CAS
PubMed

Google Scholar

O’Bryant, S. E., Petersen, M., Hall, J. & Johnson, L. A. Medical comorbidities and ethnicity impact plasma Alzheimer’s disease biomarkers: Important considerations for clinical trials and practice. Alzheimers Dement. 19, 36–43 (2023).

Article
PubMed

Google Scholar

Cousins, K. A. Q. et al. CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology. Neurology 99, e2303–e2312 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Mielke, M. M. et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat. Med. 28, 1398–1405 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Galimberti, D. & Scarpini, E. Old and new acetylcholinesterase inhibitors for Alzheimer’s disease. Expert Opin. Investig. Drugs 25, 1181–1187 (2016).

Article
CAS
PubMed

Google Scholar

Masters, C. L. et al. Alzheimer’s disease. Nat. Rev. Dis. Prim. 1, 15056 (2015).

Article
PubMed

Google Scholar

Akıncıoğlu, H. & Gülçin, İ. Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer’s Disease. Mini Rev. Med. Chem. 20, 703–715 (2020).

Article
PubMed

Google Scholar

Simunkova, M. et al. Management of oxidative stress and other pathologies in Alzheimer’s disease. Arch. Toxicol. 93, 2491–2513 (2019).

Article
CAS
PubMed

Google Scholar

Thompson, S., Lanctôt, K. L. & Herrmann, N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease. Expert Opin. Drug Saf. 3, 425–440 (2004).

Article
CAS
PubMed

Google Scholar

Nunes, D., Loureiro, J. A. & Pereira, M. C. Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s. Drugs Pharm. 14, 2296 (2022).

CAS

Google Scholar

Kabir, M. T. et al. Combination Drug Therapy for the Management of Alzheimer’s Disease. Int. J. Mol. Sci. 21, 3272 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Joe, E. & Ringman, J. M. Cognitive symptoms of Alzheimer’s disease: clinical management and prevention. BMJ 367, l6217 (2019).

Article
PubMed

Google Scholar

Larkin, H. D. First Donepezil Transdermal Patch Approved for Alzheimer Disease. JAMA 327, 1642 (2022).

PubMed

Google Scholar

Tariot, P. N., Braeckman, R. & Oh, C. Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil. J. Alzheimers Dis. 90, 161–172 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Taléns-Visconti, R. et al. Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications. Pharmaceutics 15, 1399 (2023).

Article
PubMed
PubMed Central

Google Scholar

Georgieva, D., Nikolova, D., Vassileva, E. & Kostova, B. Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer’s Disease Therapy. Pharmaceutics 15, 829 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Amat-Ur-Rasool, H., Ahmed, M., Hasnain, S. & Carter, W. G. Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease. Brain Sci. 11, 184 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Miculas, D. C. et al. Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions. Cells 12, 131 (2022).

Article
PubMed
PubMed Central

Google Scholar

Pardo-Moreno, T. et al. Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives. Pharmaceutics 14, 1117 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Huang, L. K., Chao, S. P. & Hu, C. J. Clinical trials of new drugs for Alzheimer disease. J. Biomed. Sci. 27, 18 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Cummings, J. & Fox, N. Defining Disease Modifying Therapy for Alzheimer’s Disease. J. Prev. Alzheimers Dis. 4, 109–115 (2017).

CAS
PubMed
PubMed Central

Google Scholar

Yeo-Teh, N. S. L. & Tang, B. L. A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer’s Disease. Sci. Eng. Ethics 29, 2 (2023).

Article
PubMed

Google Scholar

Wang, X. et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res. 29, 787–803 (2019).

Article
CAS
PubMed
PubMed Central

Google Scholar

Bosch, M. E. et al. Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner. Mol. Neurodegener. 19, 18 (2024).

Article
CAS
PubMed
PubMed Central

Google Scholar

Liu, K. Y. & Howard, R. Can we learn lessons from the FDA’s approval of aducanumab? Nat. Rev. Neurol. 17, 715–722 (2021).

Article
PubMed

Google Scholar

Lythgoe, M. P., Jenei, K. & Prasad, V. Regulatory decisions diverge over aducanumab for Alzheimer’s disease. BMJ 376, e069780 (2022).

Article
PubMed

Google Scholar

Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537, 50–56 (2016).

Article
CAS
PubMed

Google Scholar

Karran, E. & De Strooper, B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat. Rev. Drug Discov. 21, 306–318 (2022).

Article
CAS
PubMed

Google Scholar

Jucker, M. & Walker, L. C. Alzheimer’s disease: From immunotherapy to immunoprevention. Cell 186, 4260–4270 (2023).

Article
CAS
PubMed

Google Scholar

Lannfelt, L. et al. BAN2401 shows stronger binding to soluble aggregated amyloid-beta species than aducanumab. Alzheimers Dement. 15, P1601–P1602 (2019).

Article

Google Scholar

Golde, T. E. & Levey, A. I. Immunotherapies for Alzheimer’s disease. Science 382, 1242–1244 (2023).

Article
CAS
PubMed

Google Scholar

Boxer, A. L. & Sperling, R. Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials. Cell 186, 4757–4772 (2023).

Article
CAS
PubMed

Google Scholar

Couzin-Frankel, J. Side effects loom over Alzheimer’s drugs. Science 381, 466–467 (2023).

Article
CAS
PubMed

Google Scholar

Cao, Y., Yu, F., Lyu, Y. & Lu, X. Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer’s disease in China. Front. Neurol. 13, 1034243 (2022).

Article
PubMed
PubMed Central

Google Scholar

Ballard, C. Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimer Disease. JAMA Neurol. 80, 1272–1273 (2023).

Article
PubMed

Google Scholar

Almeida, O. P. & Ford, A. H. Are We Getting Better at Managing Agitation in Dementia? Am. J. Geriatr. Psychiatry 28, 401–403 (2020).

Article
PubMed

Google Scholar

Bauzon, J., Lee, G. & Cummings, J. Repurposed agents in the Alzheimer’s disease drug development pipeline. Alzheimers Res. Ther. 12, 98 (2020).

Article
PubMed
PubMed Central

Google Scholar

Grabowska, M. E. et al. Drug repurposing for Alzheimer’s disease from 2012-2022-a 10-year literature review. Front. Pharm. 14, 1257700 (2023).

Article
CAS

Google Scholar

Ballard, C. et al. Drug repositioning and repurposing for Alzheimer disease. Nat. Rev. Neurol. 16, 661–673 (2020).

Article
PubMed
PubMed Central

Google Scholar

Zang, C. et al. High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data. Nat. Commun. 14, 8180 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Rodriguez, S. et al. Machine learning identifies candidates for drug repurposing in Alzheimer’s disease. Nat. Commun. 12, 1033 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Tsuji, S. et al. Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer’s disease. Alzheimers Res. Ther. 13, 92 (2021).

Article
PubMed
PubMed Central

Google Scholar

Cummings, J. et al. Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement. 9, e12385 (2023).

Google Scholar

van Bokhoven, P. et al. The Alzheimer’s disease drug development landscape. Alzheimers Res. Ther. 13, 186 (2021).

Article
PubMed
PubMed Central

Google Scholar

Elmaleh, D. R. et al. Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions. J. Alzheimers Dis. 71, 715–732 (2019).

Article
CAS
PubMed
PubMed Central

Google Scholar

Zhang, F. et al. New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease. Acta Pharm. Sin. 42, 1382–1389 (2021).

Article
CAS

Google Scholar

Doody, R. S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N. Engl. J. Med. 369, 341–350 (2013).

Article
CAS
PubMed

Google Scholar

Blennow, K., Zetterberg, H., Haass, C. & Finucane, T. Semagacestat’s fall: where next for AD therapies? Nat. Med. 19, 1214–1215 (2013).

Article
PubMed

Google Scholar

Yang, G. et al. Structural basis of γ-secretase inhibition and modulation by small molecule drugs. Cell 184, 521–533.e14 (2021).

Article
CAS
PubMed

Google Scholar

Gupta, V. B., Gupta, V. K. & Martins, R. Semagacestat for treatment of Alzheimer’s disease. N. Engl. J. Med. 369, 1660–1661, (2013).

Article
CAS
PubMed

Google Scholar

Coric, V. et al. Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial. JAMA Neurol. 72, 1324–1333 (2015).

Article
PubMed

Google Scholar

Gravitz, L. Drugs: a tangled web of targets. Nature 475, S9–11 (2011).

Article
CAS
PubMed

Google Scholar

Hrabinova, M. et al. Is It the Twilight of BACE1 Inhibitors? Curr. Neuropharmacol. 19, 61–77 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Neumann, U. et al. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer’s disease. EMBO Mol. Med. 10, e9316 (2018).

Article
PubMed
PubMed Central

Google Scholar

Jeremic, D., Jiménez-Díaz, L. & Navarro-López, J. D. Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review. Ageing Res. Rev. 72, 101496 (2021).

Article
CAS
PubMed

Google Scholar

Walsh, T. et al. Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer’s Prevention Trial: A global Perspective from the API Generation Program. J. Prev. Alzheimers Dis. 10, 453–463 (2023).

CAS
PubMed
PubMed Central

Google Scholar

Imbimbo, B. P. & Watling, M. Investigational BACE inhibitors for the treatment of Alzheimer’s disease. Expert Opin. Investig. Drugs 28, 967–975 (2019).

Article
CAS
PubMed

Google Scholar

Navarro-Gómez, N., Valdes-Gonzalez, M., Garrido-Suárez, B. B. & Garrido, G. Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010–2020. J. Prev. Alzheimers Dis. 10, 50–68 (2023).

PubMed

Google Scholar

Tolar, M. et al. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimers Res. Ther. 12, 95 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Tolar, M., Abushakra, S. & Sabbagh, M. The path forward in Alzheimer’s disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimers Dement. 16, 1553–1560 (2020).

Article
PubMed

Google Scholar

Hoffmann, T. et al. Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice. Int J. Mol. Sci. 22, 11791 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Van Manh, N. et al. Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer’s disease agents. Eur. J. Med. Chem. 244, 114837 (2022).

Article
PubMed

Google Scholar

Scheltens, P. et al. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimers Res. Ther. 10, 107 (2018).

Article
PubMed
PubMed Central

Google Scholar

Vijverberg, E. G. B. et al. Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD. Alzheimers Res. Ther. 13, 142 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

The, L. Alzheimer’s disease: expedition into the unknown. Lancet. 388, 2713 (2016).

Sacks, C. A., Avorn, J. & Kesselheim, A. S. The Failure of Solanezumab – How the FDA Saved Taxpayers Billions. N. Engl. J. Med. 376, 1706–1708 (2017).

Article
PubMed

Google Scholar

Karran, E. & Hardy, J. Antiamyloid therapy for Alzheimer’s disease–are we on the right road? N. Engl. J. Med. 370, 377–378 (2014).

Article
CAS
PubMed

Google Scholar

Honig, L. S. et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease. N. Engl. J. Med. 378, 321–330 (2018).

Article
CAS
PubMed

Google Scholar

Bateman, R. J. et al. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease. Alzheimers Res. Ther. 14, 178 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Bateman, R. J. et al. Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease. N. Engl. J. Med. 389, 1862–1876 (2023).

Article
CAS
PubMed

Google Scholar

Schneider, L. S. What the Gantenerumab Trials Teach Us about Alzheimer’s Treatment. N. Engl. J. Med. 389, 1918–1920 (2023).

Article
CAS
PubMed

Google Scholar

Basheer, N. et al. Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials. Mol. Psychiatry 28, 2197–2214 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Dong, Y. et al. Design, synthesis and bioevaluation of 1,2,4-thiadiazolidine-3,5-dione derivatives as potential GSK-3beta inhibitors for the treatment of Alzheimer’s disease. Bioorg. Chem. 134, 106446 (2023).

Article
CAS
PubMed

Google Scholar

Gulisano, W. et al. Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade. J. Alzheimers Dis. 64, S611–S631 (2018).

Article
CAS
PubMed
PubMed Central

Google Scholar

Wilcock, G. K. et al. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. J. Alzheimers Dis. 61, 435–457 (2018).

Article
CAS
PubMed

Google Scholar

Gauthier, S. et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388, 2873–2884 (2016).

Article
CAS
PubMed
PubMed Central

Google Scholar

Wischik, C. M. et al. Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. J. Prev. Alzheimers Dis. 9, 780–790 (2022).

CAS
PubMed
PubMed Central

Google Scholar

Panza, F. et al. Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies. Expert Opin. Investig. Drugs 32, 625–634 (2023).

Article
CAS
PubMed

Google Scholar

Roberts, M. et al. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s disease. Acta Neuropathol. Commun. 8, 13 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Novak, P. et al. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease. Nat. Aging 1, 521–534 (2021).

Article
PubMed

Google Scholar

Reading, C. L., Ahlem, C. N. & Murphy, M. F. NM101 Phase III study of NE3107 in Alzheimer’s disease: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance. Neurodegener. Dis. Manag. 11, 289–298 (2021).

Article
PubMed

Google Scholar

Lozupone, M. et al. Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs. Expert Opin. Emerg. Drugs 25, 319–335 (2020).

Article
CAS
PubMed

Google Scholar

Wang, S. et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model. J. Exp. Med. 217, e20200785 (2020).

Article
PubMed
PubMed Central

Google Scholar

Ettcheto, M. et al. Masitinib for the treatment of Alzheimer’s disease. Neurodegener. Dis. Manag. 11, 263–276 (2021).

Article
PubMed

Google Scholar

Maheshwari, S. et al. Navigating the dementia landscape: Biomarkers and emerging therapies. Ageing Res. Rev. 94, 102193 (2024).

Article
CAS
PubMed

Google Scholar

Lawlor, B. et al. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Med. 15, e1002660 (2018).

Article
PubMed
PubMed Central

Google Scholar

Padhi, D. & Govindaraju, T. Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease. J. Med. Chem. 65, 7088–7105 (2022).

Article
CAS
PubMed

Google Scholar

Cacabelos, R. What have we learnt from past failures in Alzheimer’s disease drug discovery? Expert Opin. Drug Discov. 17, 309–323 (2022).

Article
PubMed

Google Scholar

Imbimbo, B. P., Watling, M., Imbimbo, C. & Nisticò, R. Plasma ATN(I) classification and precision pharmacology in Alzheimer’s disease. Alzheimers Dement. 19, 4729–4734 (2023).

Article
CAS
PubMed

Google Scholar

Tatulian, S. A. Challenges and hopes for Alzheimer’s disease. Drug Discov. Today 27, 1027–1043 (2022).

Article
PubMed

Google Scholar

Goldman, D. P., Fillit, H. & Neumann, P. Accelerating Alzheimer’s disease drug innovations from the research pipeline to patients. Alzheimers Dement. 14, 833–836 (2018).

Article
PubMed

Google Scholar

Moutinho, S. The long road to a cure for Alzheimer’s disease is paved with failures. Nat. Med. 28, 2228–2231 (2022).

Article
CAS
PubMed

Google Scholar

Zhang, L. et al. Advance of sporadic Alzheimer’s disease animal models. Med. Res. Rev. 40, 431–458 (2020).

Article
CAS
PubMed

Google Scholar

Xia, Z. D. et al. Pathogenesis, Animal Models, and Drug Discovery of Alzheimer’s Disease. J. Alzheimers Dis. 94, 1265–1301 (2023).

Article
PubMed

Google Scholar

LaFerla, F. M. & Green, K. N. Animal models of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006320 (2012).

Article
PubMed
PubMed Central

Google Scholar

Chen, Z. Y. & Zhang, Y. Animal models of Alzheimer’s disease: Applications, evaluation, and perspectives. Zool. Res. 43, 1026–1040 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Luo, Y. & Li, H. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs). Int J. Mol. Sci. 21, 8828 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Liu, C. S. et al. Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation-induced profibrotic fibroblast responses. Int. J. Cancer 151, 275–286 (2022).

Article
CAS
PubMed

Google Scholar

Yu, J., Zhang, C. & Song, C. Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances. Eur. J. Med. Chem. 238, 114516 (2022).

Article
CAS
PubMed

Google Scholar

Ghiboub, M. et al. Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives. J. Pers. Med. 11, 336 (2021).

Article
PubMed
PubMed Central

Google Scholar

Hu, X. L. et al. Stereoisomers of Schisandrin B Are Potent ATP Competitive GSK-3beta Inhibitors with Neuroprotective Effects against Alzheimer’s Disease: Stereochemistry and Biological Activity. ACS Chem. Neurosci. 10, 996–1007 (2019).

Article
CAS
PubMed

Google Scholar

Rippin, I. et al. Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site. Int J. Mol. Sci. 21, 8709 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Beurel, E., Grieco, S. F. & Jope, R. S. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharm. Ther. 148, 114–131 (2015).

Article
CAS

Google Scholar

Liang, Z. & Li, Q. X. Discovery of Selective, Substrate-Competitive, and Passive Membrane Permeable Glycogen Synthase Kinase-3beta Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling of New C-Glycosylflavones. ACS Chem. Neurosci. 9, 1166–1183 (2018).

Article
CAS
PubMed

Google Scholar

Silva-Garcia, O. et al. GSK3alpha: An Important Paralog in Neurodegenerative Disorders and Cancer. Biomolecules 10, 1683 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Amaral, B. et al. Elucidation of the GSK3alpha Structure Informs the Design of Novel, Paralog-Selective Inhibitors. ACS Chem. Neurosci. 14, 1080–1094 (2023).

Article
CAS
PubMed

Google Scholar

Wei, J. et al. Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity. Eur. J. Med. Chem. 236, 114301 (2022).

Article
CAS
PubMed

Google Scholar

Bernard-Gauthier, V. et al. Structural Basis for Achieving GSK-3beta Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery. J. Med. Chem. 62, 9600–9617 (2019).

Article
CAS
PubMed
PubMed Central

Google Scholar

Wu, Y. W. et al. Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule. Int J. Biol. Macromol. 259, 129074 (2024).

Article
CAS
PubMed

Google Scholar

Fernandez Bessone, I. et al. DYRK1A regulates the bidirectional axonal transport of APP in human-derived neurons. J. Neurosci. 42, 6344–6358 (2022).

Article
PubMed
PubMed Central

Google Scholar

Deboever, E., Fistrovich, A., Hulme, C. & Dunckley, T. The Omnipresence of DYRK1A in Human Diseases. Int J. Mol. Sci. 23, 9355 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Miyazaki, Y. et al. Structure-activity relationship for the folding intermediate-selective inhibition of DYRK1A. Eur. J. Med. Chem. 227, 113948 (2022).

Article
CAS
PubMed

Google Scholar

Bieliauskas, A. V. & Pflum, M. K. Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev. 37, 1402–1413 (2008).

Article
CAS
PubMed
PubMed Central

Google Scholar

Shukla, S. & Tekwani, B. L. Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation. Front. Pharm. 11, 537 (2020).

Article
CAS

Google Scholar

Simões-Pires, C. et al. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol. Neurodegener. 8, 7 (2013).

Article
PubMed
PubMed Central

Google Scholar

Zhang, Q. Q., Zhang, W. J. & Chang, S. HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation. Front. Immunol. 14, 1168848 (2023).

Article
PubMed
PubMed Central

Google Scholar

Vögerl, K. et al. Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors. J. Med. Chem. 62, 1138–1166 (2019).

Article
PubMed
PubMed Central

Google Scholar

Li, Y. et al. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer’s disease: A review (2010-2020). Eur. J. Med. Chem. 226, 113874 (2021).

Article
CAS
PubMed

Google Scholar

Wang, X. X., Wan, R. Z. & Liu, Z. P. Recent advances in the discovery of potent and selective HDAC6 inhibitors. Eur. J. Med. Chem. 143, 1406–1418 (2018).

Article
CAS
PubMed

Google Scholar

Wang, X. X. et al. Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer’s disease. Eur. J. Med. Chem. 225, 113821 (2021).

Article
CAS
PubMed

Google Scholar

Liang, T. et al. Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharm. Sin. B 13, 2425–2463 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

He, F. et al. Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer’s Disease Mouse Model. J. Med. Chem. 64, 3794–3812 (2021).

Article
CAS
PubMed

Google Scholar

Lee, H. Y. et al. 5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer’s Disease Phenotypes. J. Med. Chem. 61, 7087–7102 (2018).

Article
CAS
PubMed

Google Scholar

Cescon, E. et al. Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 delta Inhibitors. ACS Med. Chem. Lett. 11, 1168–1174 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Cho, H. & Hah, J.-M. J. B. A perspective on the development of c-jun N-terminal kinase inhibitors as therapeutics for alzheimer’s disease: Investigating structure through docking studies. Biomedicines 9, 1431 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Kim, M. H. et al. Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1H-benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects. Bioorg. Med. Chem. 21, 2271–2285 (2013).

Article
CAS
PubMed

Google Scholar

Jang, M. et al. Discovery of 1-Pyrimidinyl-2-Aryl-4,6-Dihydropyrrolo [3,4-d]Imidazole-5(1H)-Carboxamide as a Novel JNK Inhibitor. Int J. Mol. Sci. 21, 1698 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Jun, J. et al. Discovery of novel imidazole chemotypes as isoform-selective JNK3 inhibitors for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 245, 114894 (2023).

Article
CAS
PubMed

Google Scholar

Guenette, R. G. et al. Target and tissue selectivity of PROTAC degraders. Chem. Soc. Rev. 51, 5740–5756 (2022).

Article
CAS
PubMed

Google Scholar

Sutanto, F., Konstantinidou, M. & Dömling, A. Covalent inhibitors: a rational approach to drug discovery. RSC Med. Chem. 11, 876–884 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Cescon, E. et al. Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 δ Inhibitors. ACS Med. Chem. Lett. 11, 1168–1174 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Maramai, S., Benchekroun, M., Gabr, M. T. & Yahiaoui, S. Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations. Biomed. Res. Int. 2020, 5120230 (2020).

Article
PubMed
PubMed Central

Google Scholar

Zou, D. et al. Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer’s disease. J. Enzym. Inhib. Med. Chem. 38, 2270781 (2023).

Article

Google Scholar

Raghavendra, N. M. et al. Dual or multi-targeting inhibitors: The next generation anticancer agents. Eur. J. Med. Chem. 143, 1277–1300 (2018).

Article
CAS
PubMed

Google Scholar

Ferreira, J. P. S. et al. Dual-target compounds for Alzheimer’s disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR). Eur. J. Med. Chem. 221, 113492 (2021).

Article
CAS
PubMed

Google Scholar

Miao, S. et al. Aaptamine – a dual acetyl – and butyrylcholinesterase inhibitor as potential anti-Alzheimer’s disease agent. Pharm. Biol. 60, 1502–1510 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Makhaeva, G. F. et al. New Hybrids of 4-Amino-2,3-polymethylene-quinoline and p-Tolylsulfonamide as Dual Inhibitors of Acetyl- and Butyrylcholinesterase and Potential Multifunctional Agents for Alzheimer’s Disease Treatment. Molecules 25, 3915 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Bondzic, A. M. et al. Aminoalcoholate-driven tetracopper(II) cores as dual acetyl and butyrylcholinesterase inhibitors: Experimental and theoretical elucidation of mechanism of action. J. Inorg. Biochem. 205, 110990 (2020).

Article
CAS
PubMed

Google Scholar

Viayna, E. et al. Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice. J. Med. Chem. 64, 812–839 (2021).

Article
CAS
PubMed

Google Scholar

He, Q. et al. Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer’s disease: Design, synthesis and biological evaluation. Bioorg. Chem. 81, 512–528 (2018).

Article
CAS
PubMed

Google Scholar

Li, X. et al. Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer’s Disease. ACS Chem. Neurosci. 13, 3488–3501 (2022).

Article
CAS
PubMed

Google Scholar

Schneider, L. S. et al. Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial. Neurology 93, e1474–e1484 (2019).

Article
CAS
PubMed
PubMed Central

Google Scholar

Stern, N. et al. Dual Inhibitors of AChE and BACE-1 for Reducing Abeta in Alzheimer’s Disease: From In Silico to In Vivo. Int. J. Mol. Sci. 23, 13098 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Fronza, M. G., Alves, D., Praticò, D. & Savegnago, L. The neurobiology and therapeutic potential of multi-targeting β-secretase, glycogen synthase kinase 3β and acetylcholinesterase in Alzheimer’s disease. Ageing Res. Rev. 90, 102033 (2023).

Article
CAS
PubMed

Google Scholar

Jiang, X. Y. et al. Dual GSK-3beta/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer’s Disease Drug Discovery. ACS Med. Chem. Lett. 9, 171–176 (2018).

Article
CAS
PubMed
PubMed Central

Google Scholar

Jiang, X. et al. Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer’s disease. Eur. J. Med. Chem. 207, 112751 (2020).

Article
CAS
PubMed

Google Scholar

Swetha, R. et al. Combined ligand-based and structure-based design of PDE 9A inhibitors against Alzheimer’s disease. Mol. Divers. 26, 2877–2892 (2022).

Article
CAS
PubMed

Google Scholar

Sheng, J. et al. Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer’s disease. Front. Aging Neurosci. 14, 1019187 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Liu, J. et al. Discovery of novel 2,3-dihydro-1H-inden-1-ones as dual PDE4/AChE inhibitors with more potency against neuroinflammation for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 238, 114503 (2022).

Article
CAS
PubMed

Google Scholar

Liu, Y. et al. Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. J. Hematol. Oncol. 15, 89 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Jakubik, J. & El-Fakahany, E. E. Current Advances in Allosteric Modulation of Muscarinic Receptors. Biomolecules 10, 325 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Xie, X. et al. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials. Signal Transduct. Target Ther. 8, 335 (2023).

Article
PubMed
PubMed Central

Google Scholar

Dwomoh, L., Tejeda, G. S. & Tobin, A. B. Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease. Neuronal. Signal 6, NS20210004 (2022).

Article
PubMed
PubMed Central

Google Scholar

van der Westhuizen, E. T. et al. Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias. Front. Pharm. 11, 606656 (2020).

Article

Google Scholar

Luo, J. E. & Li, Y. M. Turning the tide on Alzheimer’s disease: modulation of γ-secretase. Cell Biosci. 12, 2 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

De Strooper, B. & Karran, E. New precision medicine avenues to the prevention of Alzheimer’s disease from insights into the structure and function of γ-secretases. EMBO J. 43, 887–903 (2024).

Article
PubMed
PubMed Central

Google Scholar

Rynearson, K. D. et al. Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention. J. Exp. Med. 218, e20202560 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Hollingsworth, S. A. et al. Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs. Nat. Commun. 10, 3289 (2019).

Article
PubMed
PubMed Central

Google Scholar

Terry, A. V. Jr., Jones, K. & Bertrand, D. Nicotinic acetylcholine receptors in neurological and psychiatric diseases. Pharm. Res. 191, 106764 (2023).

Article
CAS

Google Scholar

Letsinger, A. C., Gu, Z. & Yakel, J. L. α7 nicotinic acetylcholine receptors in the hippocampal circuit: taming complexity. Trends Neurosci. 45, 145–157 (2022).

Article
CAS
PubMed

Google Scholar

Sinha, N. et al. Discovery of Novel, Potent, Brain-Permeable, and Orally Efficacious Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptor [4-(5-(4-Chlorophenyl)-4-methyl-2-propionylthiophen-3-yl)benzenesulfonamide]: Structure-Activity Relationship and Preclinical Characterization. J. Med. Chem. 63, 944–960 (2020).

Kurimoto, E. et al. An Approach to Discovering Novel Muscarinic M(1) Receptor Positive Allosteric Modulators with Potent Cognitive Improvement and Minimized Gastrointestinal Dysfunction. J. Pharm. Exp. Ther. 364, 28–37 (2018).

Article
CAS

Google Scholar

Jörg, M. et al. 6-Phenylpyrimidin-4-ones as Positive Allosteric Modulators at the M(1) mAChR: The Determinants of Allosteric Activity. ACS Chem. Neurosci. 10, 1099–1114 (2019).

Article
PubMed

Google Scholar

Dallagnol, J. C. C. et al. Synthesis and Pharmacological Evaluation of Heterocyclic Carboxamides: Positive Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor with Weak Agonist Activity and Diverse Modulatory Profiles. J. Med. Chem. 61, 2875–2894 (2018).

Article
CAS
PubMed

Google Scholar

Querfurth, H. et al. A PDK-1 allosteric agonist neutralizes insulin signaling derangements and beta-amyloid toxicity in neuronal cells and in vitro. PLoS One 17, e0261696 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Dahlstrom, M. et al. Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction. Cells 10, 1871 (2021).

Article
PubMed
PubMed Central

Google Scholar

Önnestam, K. et al. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects. J. Prev. Alzheimers Dis. 10, 778–789 (2023).

PubMed

Google Scholar

Chen, L. et al. Advances in RIPK1 kinase inhibitors. Front. Pharm. 13, 976435 (2022).

Article
CAS

Google Scholar

Geoffroy, C., Paoletti, P. & Mony, L. Positive allosteric modulation of NMDA receptors: mechanisms, physiological impact and therapeutic potential. J. Physiol. 600, 233–259 (2022).

Article
CAS
PubMed

Google Scholar

Balboni, B. et al. GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier? Int. J. Mol. Sci. 24, 7541 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 1, 198–210 (2002).

Article
CAS
PubMed

Google Scholar

Mannes, M., Martin, C., Menet, C. & Ballet, S. Wandering beyond small molecules: peptides as allosteric protein modulators. Trends Pharm. Sci. 43, 406–423 (2022).

Article
CAS
PubMed

Google Scholar

Coughlin, Q. et al. Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases. J. Med. Chem. 62, 5979–6002 (2019).

Article
CAS
PubMed

Google Scholar

Zheng, L. et al. Development of covalent inhibitors: Principle, design, and application in cancer. MedComm. Oncol. 2, e56 (2023).

Article

Google Scholar

Cully, M. Novel chemistry for covalent inhibitors. Nat. Rev. Drug Discov. 19, 754 (2020).

Article
CAS
PubMed

Google Scholar

Abdeldayem, A. et al. Advances in covalent kinase inhibitors. Chem. Soc. Rev. 49, 2617–2687 (2020).

Article
CAS
PubMed

Google Scholar

Jones, M. R. et al. Modulation of the Aβ peptide aggregation pathway by KP1019 limits Aβ-associated neurotoxicity. Metallomics 7, 129–135 (2015).

Article
CAS
PubMed

Google Scholar

Eden, A. et al. Covalent fragment inhibits intramembrane proteolysis. Front. Mol. Biosci. 9, 958399 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Zhou, R. et al. Recognition of the amyloid precursor protein by human γ-secretase. Science 363, eaaw0930 (2019).

Article
CAS
PubMed

Google Scholar

Schaefer, D. & Cheng, X. Recent Advances in Covalent Drug Discovery. Pharmaceuticals 16, 663 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

McCormick, F. Sticking it to KRAS: Covalent Inhibitors Enter the Clinic. Cancer Cell 37, 3–4 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Baillie, T. A. Targeted Covalent Inhibitors for Drug Design. Angew. Chem. Int. Ed. Engl. 55, 13408–13421 (2016).

Article
CAS
PubMed

Google Scholar

Bhatia, S., Singh, M., Singh, T. & Singh, V. Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer’s Disease. Neurochem. Res. 48, 13–25 (2023).

Article
CAS
PubMed

Google Scholar

Fang, Y. et al. Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy. J. Med. Chem. 65, 11454–11477 (2022).

Article
CAS
PubMed

Google Scholar

Qu, L. et al. Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer’s disease. Eur. J. Med. Chem. 226, 113889 (2021).

Article
CAS
PubMed

Google Scholar

Sibley, C. D. & Schneekloth, J. S. Heterobifunctional molecules tackle targeted protein dephosphorylation. Trends Pharm. Sci. 43, 263–265 (2022).

Article
CAS
PubMed

Google Scholar

Hu, Z. et al. Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality. J. Am. Chem. Soc. 145, 4045–4055 (2023).

Article
CAS

Google Scholar

Wu, D. et al. Small molecules targeting protein-protein interactions for cancer therapy. Acta Pharm. Sin. B 13, 4060–4088 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Kumar, V. & Roy, K. Protein-protein interaction network analysis for the identification of novel multi-target inhibitors and target miRNAs against Alzheimer’s disease. Adv. Protein Chem. Struct. Biol. 139, 405–467 (2024).

Article
PubMed

Google Scholar

Chen, H. et al. Network integration and protein structural binding analysis of neurodegeneration-related interactome. Brief. Bioinform. 24, bbad237 (2023).

Article
PubMed

Google Scholar

Ganeshpurkar, A. et al. Protein-Protein Interactions and Aggregation Inhibitors in Alzheimer’s Disease. Curr. Top. Med. Chem. 19, 501–533 (2019).

Article
CAS
PubMed

Google Scholar

Santini, B. L. & Zacharias, M. Rapid in silico Design of Potential Cyclic Peptide Binders Targeting Protein-Protein Interfaces. Front. Chem. 8, 573259 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Lee, A. C., Harris, J. L., Khanna, K. K. & Hong, J. H. A Comprehensive Review on Current Advances in Peptide Drug Development and Design. Int. J. Mol. Sci. 20, 2383 (2019).

Article
PubMed
PubMed Central

Google Scholar

Zhao, P. et al. LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions. Mol. Neurodegener. 17, 44 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Cao, Q. et al. Inhibiting amyloid-β cytotoxicity through its interaction with the cell surface receptor LilrB2 by structure-based design. Nat. Chem. 10, 1213–1221 (2018).

Article
CAS
PubMed
PubMed Central

Google Scholar

Lao, K. et al. Identification of novel Aβ-LilrB2 inhibitors as potential therapeutic agents for Alzheimer’s disease. Mol. Cell Neurosci. 114, 103630 (2021).

Article
CAS
PubMed

Google Scholar

Ciccone, L. et al. The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1. Molecules 25, 2439 (2020).

Article
CAS
PubMed
PubMed Central

Google Scholar

Cotrina, E. Y. et al. Targeting transthyretin in Alzheimer’s disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer’s disease. Eur. J. Med. Chem. 226, 113847 (2021).

Article
CAS
PubMed

Google Scholar

Sun, Y. et al. Direct inhibition of Keap1-Nrf2 Protein-Protein interaction as a potential therapeutic strategy for Alzheimer’s disease. Bioorg. Chem. 103, 104172 (2020).

Article
CAS
PubMed

Google Scholar

Sun, Y. et al. A potent phosphodiester Keap1-Nrf2 protein-protein interaction inhibitor as the efficient treatment of Alzheimer’s disease. Redox Biol. 64, 102793 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Georgakopoulos, N. et al. Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein-Protein Interaction Inhibitors with an Alternative Binding Mode. J. Med. Chem. 65, 7380–7398 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Modell, A. E., Blosser, S. L. & Arora, P. S. Systematic Targeting of Protein-Protein Interactions. Trends Pharm. Sci. 37, 702–713 (2016).

Article
CAS
PubMed

Google Scholar

Jungbauer, G. et al. Periodontal microorganisms and Alzheimer disease–A causative relationship? Periodontol. 2000 89, 59–82 (2022).

Article
PubMed
PubMed Central

Google Scholar

Ryder, M. I. & Xenoudi, P. Alzheimer disease and the periodontal patient: New insights, connections, and therapies. Periodontol. 2000 87, 32–42 (2021).

Article
PubMed

Google Scholar

Ganz, T., Fainstein, N. & Ben-Hur, T. When the infectious environment meets the AD brain. Mol. Neurodegener. 17, 53 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Komaroff, A. L. Can Infections Cause Alzheimer Disease? JAMA 324, 239–240 (2020).

Article
PubMed

Google Scholar

Marcocci, M. E. et al. Herpes Simplex Virus-1 in the Brain: The Dark Side of a Sneaky Infection. Trends Microbiol. 28, 808–820 (2020).

Article
CAS
PubMed

Google Scholar

Wang, Y. et al. MAMDC2, a gene highly expressed in microglia in experimental models of Alzheimers Disease, positively regulates the innate antiviral response during neurotropic virus infection. J. Infect. 84, 187–204 (2022).

Article
CAS
PubMed

Google Scholar

Albaret, M. A. et al. HSV-1 cellular model reveals links between aggresome formation and early step of Alzheimer’s disease. Transl. Psychiatry 13, 86 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Zhao, M. et al. Microbial infection promotes amyloid pathology in a mouse model of Alzheimer’s disease via modulating γ-secretase. Mol. Psychiatry 29, 1491–1500 (2024).

Article
CAS
PubMed

Google Scholar

Golzari-Sorkheh, M., Weaver, D. F. & Reed, M. A. COVID-19 as a Risk Factor for Alzheimer’s Disease. J. Alzheimers Dis. 91, 1–23 (2023).

Article
CAS
PubMed

Google Scholar

Wang, L. et al. Association of COVID-19 with New-Onset Alzheimer’s Disease. J. Alzheimers Dis. 89, 411–414 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Wang, Q., Davis, P. B., Gurney, M. E. & Xu, R. COVID-19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement. 17, 1297–1306 (2021).

Article
CAS
PubMed

Google Scholar

Zhang, H. et al. APOE interacts with ACE2 inhibiting SARS-CoV-2 cellular entry and inflammation in COVID-19 patients. Signal Transduct. Target Ther. 7, 261 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Magusali, N. et al. A genetic link between risk for Alzheimer’s disease and severe COVID-19 outcomes via the OAS1 gene. Brain 144, 3727–3741 (2021).

Article
PubMed
PubMed Central

Google Scholar

Ma, G. et al. SARS-CoV-2 Spike protein S2 subunit modulates γ-secretase and enhances amyloid-β production in COVID-19 neuropathy. Cell Discov. 8, 99 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Liu, S. et al. Highly efficient intercellular spreading of protein misfolding mediated by viral ligand-receptor interactions. Nat. Commun. 12, 5739 (2021).

Article
CAS
PubMed
PubMed Central

Google Scholar

Mansour, H. M. The interference between SARS-COV-2 and Alzheimer’s disease: Potential immunological and neurobiological crosstalk from a kinase perspective reveals a delayed pandemic. Ageing Res. Rev. 94, 102195 (2024).

Article
CAS
PubMed

Google Scholar

Wang, Y. et al. Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer’s disease: findings based on urine proteomics and machine learning. Alzheimers Res. Ther. 15, 191 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Ashton, N. J., Ide, M., Zetterberg, H. & Blennow, K. Salivary biomarkers for Alzheimer’s disease and related disorders. Neurol. Ther. 8, 83–94 (2019).

Article
PubMed
PubMed Central

Google Scholar

Alber, J. et al. Developing retinal biomarkers for the earliest stages of Alzheimer’s disease: What we know, what we don’t, and how to move forward. Alzheimers Dement. 16, 229–243 (2020).

Article
PubMed

Google Scholar

Pun, F. W., Ozerov, I. V. & Zhavoronkov, A. AI-powered therapeutic target discovery. Trends Pharm. Sci. 44, 561–572 (2023).

Article
CAS
PubMed

Google Scholar

Cheng, F. et al. Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer’s disease. Cell Rep. Med. 5, 101379 (2024).

Article
CAS
PubMed
PubMed Central

Google Scholar

Xu, J. et al. Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer’s disease. Cell Rep. 41, 111717 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Geng, C., Wang, Z. & Tang, Y. Machine learning in Alzheimer’s disease drug discovery and target identification. Ageing Res. Rev. 93, 102172 (2024).

Article
CAS
PubMed

Google Scholar

Winchester, L. M. et al. Artificial intelligence for biomarker discovery in Alzheimer’s disease and dementia. Alzheimers Dement. 19, 5860–5871 (2023).

Article
PubMed

Google Scholar

Qiu, S. et al. Multimodal deep learning for Alzheimer’s disease dementia assessment. Nat. Commun. 13, 3404 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Francis, P. T., Palmer, A. M., Snape, M. & Wilcock, G. K. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 66, 137–147 (1999).

Article
CAS
PubMed
PubMed Central

Google Scholar

Whitehouse, P. J. et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10, 122–126 (1981).

Article
CAS
PubMed

Google Scholar

Lawlor, B. A. & Davis, K. L. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer’s disease? Biol. Psychiatry 31, 337–350 (1992).

Article
CAS
PubMed

Google Scholar

Hardy, J. & Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharm. Sci. 12, 383–388 (1991).

Article
CAS
PubMed

Google Scholar

Regland, B. & Gottfries, C. G. The role of amyloid beta-protein in Alzheimer’s disease. Lancet 340, 467–469 (1992).

Article
CAS
PubMed

Google Scholar

Goedert, M. Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Trends Neurosci. 16, 460–465 (1993).

Article
CAS
PubMed

Google Scholar

Mandelkow, E. M. & Mandelkow, E. Tau in Alzheimer’s disease. Trends Cell Biol. 8, 425–427 (1998).

Article
CAS
PubMed

Google Scholar

Aisen, P. S. & Davis, K. L. Inflammatory mechanisms in Alzheimer’s disease: implications for therapy. Am. J. Psychiatry 151, 1105–1113 (1994).

Article
CAS
PubMed

Google Scholar

Heppner, F. L., Ransohoff, R. M. & Becher, B. Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 16, 358–372 (2015).

Article
CAS
PubMed

Google Scholar

Chen, C. et al. Gut microbiota regulate Alzheimer’s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation. Gut 71, 2233–2252 (2022).

Article
PubMed

Google Scholar

Chandra, S., Sisodia, S. S. & Vassar, R. J. The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored. Mol. Neurodegener. 18, 9 (2023).

Article
PubMed
PubMed Central

Google Scholar

Bush, A. I. et al. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 265, 1464–1467 (1994).

Article
CAS
PubMed

Google Scholar

Zatta, P., Drago, D., Bolognin, S. & Sensi, S. L. Alzheimer’s disease, metal ions and metal homeostatic therapy. Trends Pharm. Sci. 30, 346–355, (2009).

Article
CAS
PubMed

Google Scholar

Tzioras, M., McGeachan, R. I., Durrant, C. S. & Spires-Jones, T. L. Synaptic degeneration in Alzheimer disease. Nat. Rev. Neurol. 19, 19–38 (2023).

Article
PubMed

Google Scholar

Zhang, Y. et al. Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future. Signal Transduct. Target Ther. 8, 248 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Kaur, D., Sharma, V. & Deshmukh, R. Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer’s disease. Inflammopharmacology 27, 663–677 (2019).

Article
PubMed

Google Scholar

Stanca, S., Rossetti, M. & Bongioanni, P. Astrocytes as Neuroimmunocytes in Alzheimer’s Disease: A Biochemical Tool in the Neuron-Glia Crosstalk along the Pathogenetic Pathways. Int J. Mol. Sci. 24, 13880 (2023).

Article
CAS
PubMed
PubMed Central

Google Scholar

Arranz, A. M. & De Strooper, B. The role of astroglia in Alzheimer’s disease: pathophysiology and clinical implications. Lancet Neurol. 18, 406–414 (2019).

Article
CAS
PubMed

Google Scholar

Sarkar, S. & Biswas, S. C. Astrocyte subtype-specific approach to Alzheimer’s disease treatment. Neurochem Int. 145, 104956 (2021).

Article
CAS
PubMed

Google Scholar

Colonna, M. The biology of TREM receptors. Nat. Rev. Immunol. 23, 580–594 (2023).

Article
CAS
PubMed

Google Scholar

Qin, Q. et al. TREM2, microglia, and Alzheimer’s disease. Mech. Ageing Dev. 195, 111438 (2021).

Article
CAS
PubMed

Google Scholar

Ulland, T. K. & Colonna, M. TREM2 – a key player in microglial biology and Alzheimer disease. Nat. Rev. Neurol. 14, 667–675 (2018).

Article
CAS
PubMed

Google Scholar

Song, W. M. et al. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J. Exp. Med. 215, 745–760 (2018).

Article
CAS
PubMed
PubMed Central

Google Scholar

Lessard, C. B. et al. High-affinity interactions and signal transduction between Aβ oligomers and TREM2. EMBO Mol. Med. 10, e9027 (2018).

Article
PubMed
PubMed Central

Google Scholar

Wang, S. et al. TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. Cell 185, 4153–4169.e4119 (2022).

Article
CAS
PubMed
PubMed Central

Google Scholar

Custodia, A. et al. Endothelial Progenitor Cells and Vascular Alterations in Alzheimer’s Disease. Front Aging Neurosci. 13, 811210 (2021).

Article
CAS
PubMed

Google Scholar

Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies

You may also like...

Recent Posts

Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies

You may also like...

Why spend Christmas on a TUI river cruise? 10 reasons why it's better than staying at home

Arizona Lottery Powerball, The Pick results for August 28, 2024

Station Film welcomes comedy director Sara Shelton

Recent Posts